{"100-1.\n\u95dc\u65bc\u8b6b\u5984(delirium)\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u6f5b\u5728\u8eab\u9ad4\u75be\u75c5\u7d93\u5e38\u662f\u9020\u6210\u8b6b\u5984\u7684\u4e3b\u8981\u539f\u56e0\nB. \u6295\u4e88\u6297\u7cbe\u795e\u75c5\u85e5\u662f\u6cbb\u7642\u8b6b\u5984\u7684\u5fc5\u8981\u6b65\u9a5f\nC. \u6709\u7814\u7a76\u986f\u793a\u8b6b\u5984\u7684\u767c\u751f\u8207\u65e5\u5f8c\u500b\u6848\u7684\u6b7b\u4ea1\u98a8\u96aa\u76f8\u95dc\nD. Benzodiazepine\u4e5f\u662f\u85e5\u7269\u6cbb\u7642\u8b6b\u5984\u7684\u9078\u9805\u4e4b\u4e00\nE. \u63d0\u4f9b\u5b89\u5168\u7684\u7167\u8b77\u74b0\u5883\u4e5f\u662f\u8655\u7f6e\u8b6b\u5984\u4e0d\u53ef\u6216\u7f3a\u4e4b\u4e00\u74b0\n": "(B)", "100-2.\n\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u7f8e\u570b\u7cbe\u795e\u91ab\u5b78\u6703\u9812\u5e03\u7cbe\u795e\u75be\u75c5\u8a3a\u65b7\u53ca\u7d71\u8a08\u624b\u518a\u4fee\u8a02\u7b2c\u56db\u7248(DSM-IV-TR)\u6240\u5b9a\u7fa9\u7684\u6050\u614c\u767c\u4f5c(panic attack)\u75c7\u72c0\uff1f\nA. \u5fc3\u60b8(palpitation)\nB. \u80f8\u60b6(chest pain)\nC. \u5641\u5fc3(nausea)\nD. \u982d\u6688(dizzy)\nE. \u53e3\u4e7e(dry mouth)\n": "(E)", "100-3.\n\u95dc\u65bc\u908a\u7de3\u6027\u4eba\u683c\u75be\u60a3(borderline personality disorder)\u7684\u63cf\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u500b\u6848\u53ef\u80fd\u56e0\u70ba\u53cd\u8986\u6027\u7684\u81ea\u6bba\u884c\u70ba\u800c\u51fa\u73fe\u5728\u6025\u8a3a\nB. \u500b\u6848\u5c0d\u65bc\u4eba\u969b\u95dc\u4fc2\u5341\u5206\u654f\u611f\uff0c\u7279\u5225\u5bb3\u6015\u88ab\u5176\u6240\u4f9d\u8cf4\u7684\u4eba\u907a\u68c4\nC. \u65b0\u4e00\u4ee3\u6297\u7cbe\u795e\u75c5\u85e5\u53ef\u4ee5\u505a\u70ba\u8f14\u52a9\u6cbb\u7642\u7684\u9078\u9805\nD. \u8fa8\u8b49\u5f0f\u884c\u70ba\u6cbb\u7642(dialectical behavior therapy)\u88ab\u8b49\u5be6\u5c0d\u6b64\u985e\u75c5\u60a3\u6709\u7642\u6548\nE. \u9078\u64c7\u6027\u8840\u6e05\u7d20\u518d\u5438\u6536\u6291\u5236\u5291(SSRI)\u662f\u908a\u7de3\u6027\u4eba\u683c\u75be\u60a3\u7684\u9996\u9078\u6cbb\u7642\u65b9\u5f0f\n": "(E)", "100-4.\n\u95dc\u65bc\u6162\u6027\u975e\u764c\u75c7\u75bc\u75db(chronic non-cancer pain)\u7684\u85e5\u7269\u6cbb\u7642\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u5728\u773e\u591a\u6297\u6182\u9b31\u85e5\u7576\u4e2d\uff0c\u4e09\u74b0\u6297\u6182\u9b31\u85e5\u7684\u6587\u737b\u8b49\u64da\u6700\u70ba\u5145\u8db3\nB. \u76ee\u524d\u8b49\u64da\u986f\u793a\u300c\u9078\u64c7\u6027\u8840\u6e05\u7d20\u518d\u5438\u6536\u6291\u5236\u5291\u300d(SSRI)\u8981\u6bd4\u300c\u9078\u64c7\u6027\u8840\u6e05\u7d20\u53ca\u65b0\u814e\u4e0a\u817a\u7d20\u518d\u5438\u6536\u6291\u5236\u5291\u300d(SNRI)\u6709\u66f4\u597d\u7684\u6b62\u75db\u6548\u679c\nC. \u6297\u7672\u7647\u85e5\u7269\u4f8b\u5982carbamazepine, gabapentine, \u4ee5\u53capregabalin\u7b49\uff0c\u4e5f\u88ab\u8b49\u5be6\u5c0d\u6162\u6027\u975e\u764c\u75c7\u75bc\u75db\u6709\u7642\u6548\nD. \u6295\u4e88\u4e09\u74b0\u6297\u6182\u9b31\u85e5\u6642\u9808\u6ce8\u610f\u59ff\u52e2\u6027\u4f4e\u8840\u58d3\u4ee5\u53ca\u5fc3\u5f8b\u4e0d\u6574\u7b49\u526f\u4f5c\u7528\nE. \u5c40\u90e8\u5857\u62b9\u8fa3\u6912\u7d20(capsaicin)\u4e5f\u88ab\u8b49\u5be6\u5c0d\u6162\u6027\u975e\u764c\u75c7\u75bc\u75db\u6709\u7642\u6548\n": "(B)", "100-5.\n\u95dc\u65bc\u81ea\u6bba\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u66fe\u7d93\u81ea\u6bba\u672a\u9042\u7684\u500b\u6848\uff0c\u65e5\u5f8c\u4e0d\u5e78\u6b7b\u65bc\u81ea\u6bba\u7684\u98a8\u96aa\u8f03\u4e00\u822c\u4eba\u9ad8\nB. \u4e00\u822c\u800c\u8a00\u7537\u6027\u81ea\u6bba\u8eab\u4ea1\u7684\u98a8\u96aa\u6bd4\u5973\u6027\u9ad8\nC. \u4e00\u822c\u800c\u8a00\u5973\u6027\u81ea\u6bba\u672a\u9042\u7684\u98a8\u96aa\u6bd4\u7537\u6027\u9ad8\nD. \u5728\u53f0\u7063\u5e74\u9f61\u5c64\u8d8a\u9ad8\u81ea\u6bba\u98a8\u96aa\u8d8a\u9ad8\nE. 50%\u5de6\u53f3\u7684\u91cd\u5ea6\u6182\u9b31\u75c7\u7684\u60a3\u8005\u6700\u7d42\u6703\u6b7b\u65bc\u81ea\u6bba\n": "(E)", "100-6.\n\u4e0b\u5217\u4f55\u7a2e\u85e5\u7269\u4e26\u975e\u4e00\u822c\u7528\u65bc\u5354\u52a9\u75c5\u60a3\u6212\u9664\u83f8\u766e(nicotine addiction)\u7684\u85e5\u7269\uff1f\nA. Varenicline\nB. Bupropion\nC. Clonidine\nD. Nortriptyline\nE. Fluvoxamine\n": "(E)", "100-7.\n\u95dc\u65bc\u91cd\u5ea6\u6182\u9b31\u75c7\u7684\u6cbb\u7642\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u662f\uff1f\r1.\u6297\u6182\u9b31\u85e5\u7269\u7684\u9078\u64c7\u5e38\u4ee5\u526f\u4f5c\u7528\u4f5c\u70ba\u8003\u91cf\u7684\u4f9d\u64da\r2.\u5f9e\u85e5\u7269\u958b\u59cb\u6295\u4e88\u5230\u7642\u6548\u986f\u8457\u9700\u8981\u56db\u81f3\u516d\u9031\r3.\u5c0d\u65bc\u6bcf\u4e00\u7a2e\u6297\u6182\u9b31\u85e5\u7269\u800c\u8a00\u90fd\u5927\u7d04\u670930%\u81f340%\u7684\u60a3\u8005\u7642\u6548\u4e0d\u4f73\r4.\u75c5\u60c5\u7a69\u5b9a\u6216\u75ca\u7652(full remission)\u5f8c\u61c9\u7acb\u5373\u505c\u85e5\u4ee5\u9632\u526f\u4f5c\u7528\r5.\u6297\u6182\u9b31\u85e5\u7269\u7684\u4ee3\u8b1d\u4e26\u7121\u660e\u986f\u7684\u7a2e\u65cf\u5dee\u7570\u3002\nA. 1+2+3\nB. 2+3+5\nC. 1+3+5\nD. 3+4+5\nE. 1+4+5\n": "(A)", "101-1.\n\u95dc\u65bc\u81ea\u6bba\u554f\u984c\u7684\u63cf\u8ff0\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u8eab\u9ad4\u75be\u75c5\u8207\u7cbe\u795e\u75be\u75c5\u662f\u81ea\u6bba\u7684\u5371\u96aa\u56e0\u5b50\nB. \u7d55\u5927\u591a\u6578\u81ea\u6bba\u8eab\u4ea1\u8005\u5f9e\u4f86\u6c92\u6709\u900f\u9732\u81ea\u6bba\u7684\u60f3\u6cd5\nC. \u5fc3\u7406\u793e\u6703\u5371\u6a5f\u4e5f\u662f\u81ea\u6bba\u7684\u5371\u96aa\u56e0\u5b50\nD. \u5a92\u9ad4\u4e0d\u9069\u7576\u5831\u5c0e\u81ea\u6bba\u4e8b\u4ef6\u6240\u5f15\u8d77\u7684\u6a21\u4eff\u6548\u61c9\u4e5f\u662f\u5371\u96aa\u56e0\u5b50\u4e4b\u4e00\nE. \u9650\u5236\u81f4\u547d\u5de5\u5177\u7684\u53ef\u5f97\u6027\u88ab\u8b49\u660e\u53ef\u4ee5\u964d\u4f4e\u81ea\u6bba\u6b7b\u4ea1\u7387\n": "(B)", "101-2.\n\u7576\u4ee3\u91ab\u75c5\u95dc\u4fc2\u7684\u6311\u6230\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u91ab\u7642\u6c7a\u7b56\u5f62\u6210\u904e\u7a0b\u4e2d\u91ab\u5e2b\u8207\u75c5\u4eba\u4e4b\u9593\u6b0a\u529b\u4f4d\u968e\u4e4b\u6539\u8b8a\nB. \u5b58\u5728\u65bc\u91ab\u75c5\u95dc\u4fc2\u4e4b\u5916\u81e8\u5e8a\u7814\u7a76\u53d7\u8a66\u8005\u8207\u7814\u7a76\u8005\u4e4b\u7279\u6b8a\u95dc\u4fc2\nC. \u5e73\u8861\u5065\u5eb7\u4fdd\u96aa\u7cfb\u7d71\u6216\u91ab\u7642\u7b2c\u4e09\u65b9(third party)\u8207\u75c5\u4eba\u6700\u5927\u5229\u76ca\u4e4b\u885d\u7a81\nD. \u500b\u9ad4\u5229\u76ca\u8207\u7fa4\u9ad4\u5229\u76ca\u4e4b\u53d6\u6368\nE. \u4ee5\u4e0a\u7686\u662f\n": "(E)", "101-3.\n\u95dc\u65bc\u8b6b\u5984\u7684\u8a55\u4f30\u8207\u8655\u7f6e\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u78ba\u5b9a\u8a3a\u65b7\u5f8c\u61c9\u7acb\u5373\u6295\u4e88\u6297\u7cbe\u795e\u75c5\u85e5\u5982 haloperidol\nB. \u6ce8\u610f\u529b\u969c\u7919\u662f\u8b6b\u5984\u7684\u91cd\u8981\u75c7\u72c0\u4e4b\u4e00\nC. \u6295\u4e88haloperidol\u6642\uff0c\u61c9\u6ce8\u610f\u5176\u662f\u5426\u589e\u52a0\u5fc3\u5f8b\u4e0d\u6574\u4e4b\u98a8\u96aa\nD. \u8b6b\u5984\u70ba\u6025\u6027\u767c\u4f5c\u4e14\u75c5\u7a0b\u8d77\u4f0f\nE. \u65e5\u591c\u9031\u671f\u6df7\u4e82\u4e5f\u6709\u53ef\u80fd\u6703\u767c\u751f\u5728\u8b6b\u5984\u75c5\u60a3\u8eab\u4e0a\n": "(A)", "101-4.\n\u95dc\u65bc\u91cd\u5ea6\u6182\u9b31\u75c7\u7684\u8a3a\u65b7\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u300c\u5c0d\u65bc\u672c\u4f86\u6709\u8208\u8da3\u7684\u4e8b\u60c5\u8b8a\u5f97\u6c92\u8208\u8da3\u300d\u662f\u6838\u5fc3\u75c7\u72c0\u4e4b\u4e00\nB. \u300c\u6301\u7e8c\u6027\u7684\u60c5\u7dd2\u4f4e\u843d\u300d\u4e5f\u662f\u6838\u5fc3\u75c7\u72c0\u4e4b\u4e00\nC. \u7336\u8c6b\u4e0d\u6c7a(undecisiveness)\u4ee5\u53ca\u6ce8\u610f\u529b\u4e0d\u96c6\u4e2d(inattentiveness)\u90fd\u662f\u91cd\u5ea6\u6182\u9b31\u75c7\u7684\u8a8d\u77e5\u75c7\u72c0\nD. \u56e0\u6182\u9b31\u60c5\u7dd2\u800c\u9020\u6210\u529f\u80fd\u640d\u5bb3\u4ee5\u53ca\u500b\u4eba\u91cd\u5927\u75db\u82e6\u662f\u5efa\u7acb\u8a3a\u65b7\u7684\u8981\u4ef6\nE. \u6027\u617e\u589e\u52a0\u4ee5\u53ca\u55dc\u7720\u591a\u7720\u4e0d\u53ef\u80fd\u767c\u751f\u5728\u91cd\u5ea6\u6182\u9b31\u75c7\u75c5\u60a3\u8eab\u4e0a\n": "(E)", "101-5.\n\u95dc\u65bc\u91cd\u5ea6\u6182\u9b31\u75c7\u7684\u751f\u7269\u5b78\u6cbb\u7642\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u9078\u64c7\u6027\u8840\u6e05\u7d20\u518d\u5438\u6536\u6291\u5236\u85e5(selective serotonin reuptake inhibitor)\u7684\u7642\u6548\u986f\u8457\u512a\u65bc\u50b3\u7d71\u4e09\u74b0\u6297\u6182\u9b31\u85e5(tricyclic antidepressant)\nB. \u5f9e\u958b\u59cb\u6295\u85e5\u5230\u6cbb\u7642\u6548\u679c\u660e\u986f\u51fa\u73fe\u5f80\u5f80\u9700\u89814\u81f36\u500b\u6708\nC. \u7167\u5149\u6cbb\u7642(light therapy)\u53ef\u4ee5\u505a\u70ba\u55ae\u7368\u7684\u4e3b\u7dda\u6cbb\u7642\nD. \u6297\u6182\u9b31\u85e5\u7269\u7684\u9078\u64c7\u9700\u8981\u8003\u616e\u60a3\u8005\u5c0d\u65bc\u5404\u7a2e\u85e5\u7269\u526f\u4f5c\u7528\u7684\u8010\u53d7\u7a0b\u5ea6\nE. \u96fb\u6c23\u75d9\u6523\u6cbb\u7642\u6cd5(electroconvulsive therapy)\u5e38\u898b\u7684\u526f\u4f5c\u7528\u70ba\u6c38\u4e45\u6027\u7684\u8a18\u61b6\u529b\u640d\u5bb3\n": "(D)", "101-6.\n\u95dc\u65bc\u5931\u7720\u75c7\u7684\u63cf\u8ff0\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u5728\u4e00\u822c\u4eba\u53e3\u7684\u76db\u884c\u7387\u7d041%\u81f32%\nB. \u7761\u7720\u885b\u751f\u6559\u80b2(sleep-hygiene education)\u662f\u6cbb\u7642\u5931\u7720\u53ef\u884c\u7684\u8fa6\u6cd5\u4e4b\u4e00\nC. \u7761\u7720\u8a8d\u77e5\u6cbb\u7642(cognitive therapy)\u7684\u5167\u5bb9\u5305\u62ec\u7834\u9664\u500b\u6848\u5c0d\u65bc\u7761\u7720\u4e4b\u8ff7\u601d\nD. \u6559\u5c0e\u75c5\u60a3\u7761\u4e0d\u8457\u5c31\u8d77\u4f86\uff0c\u6709\u7761\u610f\u518d\u56de\u5e8a\u4e0a\u7761\uff0c\u662f\u5c6c\u65bc\u523a\u6fc0\u63a7\u5236\u6cbb\u7642(stimulation-control therapy)\u4e4b\u4e00\u90e8\u5206\nE. \u6559\u5c0e\u75c5\u60a3\u653e\u9b06(relaxation training)\u4e5f\u6709\u52a9\u65bc\u8655\u7406\u5931\u7720\u7684\u554f\u984c\n": "(A)", "101-7.\n\u95dc\u65bc\u6050\u614c\u75c7(panic disorder)\u7684\u8a3a\u65b7\u8207\u6cbb\u7642\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u8207\u76f8\u95dc\u8eab\u9ad4\u75be\u75c5\u4e4b\u9451\u5225\u8a3a\u65b7\u662f\u5fc5\u8981\u7684\nB. \u4e0d\u9810\u671f\u7684\u91cd\u8907\u767c\u4f5c\u662f\u5efa\u7acb\u8a3a\u65b7\u7684\u8981\u4ef6\u4e4b\u4e00\nC. \u9078\u64c7\u6027\u8840\u6e05\u7d20\u518d\u5438\u6536\u6291\u5236\u85e5(SSRI)\u53ef\u4ee5\u4f5c\u70ba\u7b2c\u4e00\u7dda\u6cbb\u7642\u85e5\u7269\nD. \u9577\u671f\u6295\u4e88benzodiazepine\u985e\u6297\u7126\u616e\u85e5\u662f\u6700\u4f73\u7684\u6cbb\u7642\u65b9\u5f0f\nE. \u8a8d\u77e5\u884c\u70ba\u6cbb\u7642\u5c0d\u65bc\u6050\u614c\u75c7\u7684\u6cbb\u7642\u4e5f\u6709\u5e6b\u52a9\n": "(D)", "102-1.\n\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u8b6b\u5984\u75c7(delirium)\u75c5\u60a3\u5e38\u898b\u7684\u60c5\u7dd2\u884c\u70ba\u75c7\u72c0\uff1f\nA. \u610f\u8b58\u4e0d\u6e05(disturbed consciousness)\nB. \u601d\u8003\u6df7\u4e82(disorganization of thought processes)\nC. \u6ce8\u610f\u529b\u4e0d\u96c6\u4e2d(inattentiveness)\nD. \u7cfb\u7d71\u6027\u5984\u60f3(systematized delusion)\nE. \u65e5\u591c\u985b\u5012(sleep-wake cycle reversal)\n": "(D)", "102-2.\n\u95dc\u65bc\u5b89\u7720\u85e5\u7269(hypnotics)\u4e0b\u5217\u4f55\u8005\u932f\u8aa4?\nA. \u6709\u670d\u7528\u5b89\u7720\u85e5\u7269\u7684\u500b\u6848\u9700\u8981\u6ce8\u610f\u5176\u99d5\u99db\u6c7d\u6a5f\u8eca\u7684\u5b89\u5168\u6027\nB. Zolpidem\u4ee3\u8b1d\u901f\u7387\u7684\u5feb\u6162\u6709\u6027\u5225\u5dee\u7570\nC. \u7f8e\u570b\u98df\u54c1\u85e5\u7269\u7ba1\u7406\u5c40(FDA)\u5efa\u8b70\u5973\u6027\u7684Zolpidem\u8d77\u59cb\u7528\u91cf\u8981\u6bd4\u4e00\u822c\u7537\u6027\u5c11\u4e00\u534a\nD. \u500b\u6848\u5c0d\u65bc\u99d5\u99db\u529f\u80fd\u969c\u7919\u6709\u53ef\u9760\u7684\u81ea\u89ba(self-perception)\nE. \u7761\u7720\u4e0d\u8db3\u6216\u662f\u4f75\u7528\u9152\u7cbe\u6216\u5176\u4ed6\u5177\u6709\u93ae\u5b9a\u526f\u4f5c\u7528\u7684\u85e5\u7269\u540c\u6a23\u4e5f\u6703\u5f71\u97ff\u99d5\u99db\u5b89\u5168\n": "(D)", "102-3.\n\u95dc\u65bc\u8b6b\u5984(delirium)\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u6f5b\u5728\u8eab\u9ad4\u75be\u75c5\u7d93\u5e38\u662f\u9020\u6210\u8b6b\u5984\u7684\u4e3b\u8981\u539f\u56e0\nB. \u6295\u4e88\u6297\u7cbe\u795e\u75c5\u85e5\u662f\u6cbb\u7642\u8b6b\u5984\u7684\u5fc5\u8981\u6b65\u9a5f\nC. \u0013\u6709\u7814\u7a76\u986f\u793a\u8b6b\u5984\u7684\u767c\u751f\u8207\u65e5\u5f8c\u500b\u6848\u7684\u6b7b\u4ea1\u98a8\u96aa\u76f8\u95dc\nD. Benzodiazepine\u4e5f\u662f\u85e5\u7269\u6cbb\u7642\u8b6b\u5984\u7684\u9078\u9805\u4e4b\u4e00\nE. \u63d0\u4f9b\u5b89\u5168\u7684\u7167\u8b77\u74b0\u5883\u4e5f\u662f\u8655\u7f6e\u8b6b\u5984\u4e0d\u53ef\u6216\u7f3a\u4e4b\u4e00\u74b0\n": "(B)", "102-4.\n\u6839\u64da\u4e16\u754c\u885b\u751f\u7d44\u7e54(WHO)\u6700\u8fd1\u5c0d\u65bc\u91cd\u5927\u707d\u96e3\u3001\u66b4\u529b\u653b\u64ca\u3001\u610f\u5916\u4e8b\u4ef6\u3001\u6216\u662f\u89aa\u53cb\u7a81\u7136\u5f80\u751f\u5f8c\uff0c\u53ef\u80fd\u767c\u751f\u7684\u54c0\u615f\u53cd\u61c9(bereavement)\u6216\u5275\u50b7\u5f8c\u58d3\u529b\u75c7\u5019\u7fa4(post-traumatic stress disorder: PTSD)\uff0c\u5176\u8655\u7f6e\u5efa\u8b70\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u5728\u906d\u9022\u5275\u50b7\u4e8b\u4ef6\u5f8c\u7684\u982d\u4e00\u500b\u6708\u5167\uff0c\u5c0d\u65bc\u6b21\u767c\u6027\u6025\u6027\u5931\u7720(secondary acute insomnia)\u554f\u984c\uff0c\u6cbb\u7642\u9996\u9078\u70babenzodiazepines\nB. \u5728\u906d\u9022\u5275\u50b7\u4e8b\u4ef6\u982d\u4e00\u500b\u6708\u5167\u7684\u5b69\u7ae5(children)\uff0c\u82e5\u6709\u904e\u5ea6\u63db\u6c23(hyperventilation)\u554f\u984c\uff0c\u4e0d\u5efa\u8b70\u4f7f\u7528\u7d19\u888b\u518d\u547c\u5438(rebreathing into a paper bag)\u6cd5\nC. \u5728\u906d\u9022\u5275\u50b7\u4e8b\u4ef6\u4e00\u500b\u6708\u5f8c\u4e14\u7b26\u5408PTSD\u8a3a\u65b7\u7684\u6210\u5e74\u4eba\uff0c\u5efa\u8b70\u65bd\u4ee5\u500b\u5225\u6216\u5718\u9ad4\u8a8d\u77e5\u884c\u70ba\u6cbb\u7642\nD. \u5728\u906d\u9022\u5275\u50b7\u4e8b\u4ef6\u4e00\u500b\u6708\u5f8c\u4e14\u7b26\u5408PTSD\u8a3a\u65b7\u7684\u5152\u7ae5\u53ca\u9752\u5c11\u5e74\uff0c\u9078\u64c7\u6027\u8840\u6e05\u7d20\u518d\u5438\u6536\u6291\u5236\u5291(SSRI)\u4e26\u975e\u6cbb\u7642\u9996\u9078\nE. \u5c0d\u65bc\u6c92\u6709\u7cbe\u795e\u75be\u60a3\u7684\u500b\u9ad4\uff0c\u4e0d\u5efa\u8b70\u91dd\u5c0d\u54c0\u615f\u53cd\u61c9\uff0c\u65bd\u4ee5\u7d50\u69cb\u6027\u7684\u5fc3\u7406\u5b78\u4ecb\u5165(structured psychological intervention)\n": "(A)", "102-5.\n\u4e0b\u5217\u4f55\u8005\u662fDSM-IV\u5efa\u7acb\u91cd\u5ea6\u6182\u9b31\u75c7(major depression)\u8a3a\u65b7\u7684\u5178\u578b\u75c7\u72c0\uff1f(1)\u60c5\u7dd2\u4f4e\u843d (2)\u5c0d\u65bc\u672c\u4f86\u6709\u8208\u8da3\u7684\u4e8b\u60c5\u4e0d\u611f\u8208\u8da3 (3)\u7336\u8c6b\u4e0d\u6c7a (4)\u65e5\u591c\u985b\u5012 (5)\u7121\u6cd5\u63a7\u5236\u7684\u64d4\u5fc3\nA. (1)+(2)+(5)\nB. (1)+(3)+(4)\nC. (1)+(2)+(3)\nD. (3)+(4)+(5)\nE. (2)+(3)+(5)\n": "(C)", "102-6.\n\u4e0b\u5217\u4f55\u8005\u4e26\u975e\u6050\u614c\u767c\u4f5c(panic attack)\u7684\u5178\u578b\u75c7\u72c0\nA. \u5fc3\u60b8 (palpitation)\nB. \u6613\u6012\u60c5\u7dd2 (irritable mood)\nC. \u5bb3\u6015\u81ea\u5df1\u6703\u6b7b\u6389 (fear of dying)\nD. \u982d\u660f (dizzy)\nE. \u5bb3\u6015\u5931\u53bb\u63a7\u5236\u8207\u767c\u760b (fear of losing control or going crazy)\n": "(B)", "102-7.\n\u95dc\u65bc\u5404\u7a2ebenzodiazepine(BZD)\u7684\u63cf\u8ff0\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f(1)Lorazepam\u5c6c\u65bcintermediate onset\u7684BZD (2)Triazolam\u8840\u4e2d\u6fc3\u5ea6\u534a\u8870\u671f\u70ba1.5-5\u5c0f\u6642 (3)Clonazepam\u5c6c\u65bcintermediate onset\u7684BZD (4)Diazepam\u5c6c\u65bcfast onset\u7684BZD (5)Alprazolam\u7684\u8840\u4e2d\u6fc3\u5ea6\u534a\u8870\u671f\u70ba20-70\u5c0f\u6642\nA. (1)+(2)+(4)\nB. (2)+(3)+(5)\nC. (1)+(3)+(5)\nD. (2)+(3)+(4)\nE. (3)+(4)+(5)\n": "(A)", "103-1.\n\u95dc\u65bc\u8b6b\u5984(delirium)\u81e8\u5e8a\u8868\u73fe\u7684\u63cf\u8ff0\u4f55\u8005\u70ba\u975e\uff1f\nA. \u6709\u6642\u6703\u4f34\u96a8\u60c5\u7dd2\u4e0d\u7a69(emotional lability)\u5bb9\u6613\u54ed\u6ce3\u6216\u52d5\u6012\nB. \u75c5\u7a0b\u8d77\u8d77\u4f0f\u4f0f\uff0c\u6642\u597d\u6642\u58de\nC. \u6ce8\u610f\u529b\u4e0d\u96c6\u4e2d\uff1a\u9762\u8ac7\u6642\u5448\u73fe\u5fc3\u4e0d\u5728\u7109\nD. \u65e5\u591c\u898f\u5f8b\u969c\u7919(sleep-wake cycle disturbance)\uff1a\u767d\u5929\u4e00\u76f4\u7761\uff0c\u665a\u4e0a\u4e0d\u7761\nE. \u6f5b\u4f0f\u6027\u800c\u9010\u6f38\u767c\u4f5c\u7684\u610f\u8b58\u6539\u8b8a\n": "(E)", "103-2.\n\u95dc\u65bc\u5f37\u8feb\u6027\u7cbe\u795e\u5b98\u80fd\u75c7(obsessive-compulsive disorder: OCD)\u4e0b\u5217\u4f55\u8005\u70ba\u662f\uff1f(1)\u7d42\u751f\u76db\u884c\u7387(lifetime prevalence)\u5927\u7d041%\u81f33%\uff1b(2)\u6210\u5e74\u4ebaOCD\u7684\u7537\u5973\u6bd4\u4f8b\u70ba4:1\u5de6\u53f3\uff1b(3)\u6cbb\u7642\u9078\u9805\u5305\u62ec\u66b4\u9732\u7642\u6cd5(exposure therapy)\uff1b(4)\u9078\u64c7\u6027\u8840\u6e05\u7d20\u518d\u5438\u6536\u6291\u5236\u5291(SSRI)\u7684\u5efa\u8b70\u5291\u91cf\u901a\u5e38\u6bd4\u6cbb\u7642\u6182\u9b31\u75c7\u7684\u5291\u91cf\u4f86\u7684\u4f4e\uff1b(5)\u5e38\u898b\u75c7\u72c0\u53ef\u5305\u62ec\u8207\u5b97\u6559\u76f8\u95dc\u4e4b\u80cc\u5fb7(immoral)\u6216\u8a5b\u5492(dammation)\u7684\u53cd\u8986\u60f3\u6cd5\u3002\nA. (1)+(2)+(3)\nB. (1)+(3)+(5)\nC. (1)+(4)+(5)\nD. (2)+(3)+(4)\nE. (3)+(4)+(5)\n": "(B)", "103-3.\n\u95dc\u65bc\u4f7f\u7528\u5927\u9ebb(marijuana)\u5c0d\u65bc\u5065\u5eb7\u7684\u5f71\u97ff\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u77ed\u671f\u4f7f\u7528\u6703\u5f71\u97ff\u5224\u65b7\u529b(judgement)\nB. \u77ed\u671f\u4f7f\u7528\u6703\u5f71\u97ff\u52d5\u4f5c\u5354\u8abf\u6027(motor coordination)\nC. \u5438\u98df\u5927\u9ebb\u6709\u6210\u766e(addiction)\u7684\u98a8\u96aa(risk)\uff0c\u4e00\u822c\u4f7f\u7528\u8005\u67099%\u7684\u98a8\u96aa\uff0c\u5f9e\u9752\u5c11\u5e74\u5c31\u4f7f\u7528\u8005\u670917%\u7684\u98a8\u96aa\uff0c\u6bcf\u65e5\u4f7f\u7528\u8005\u98a8\u96aa\u7d0425%\u523050%\nD. \u9577\u671f\u6216\u5927\u91cf\u4f7f\u7528\u8005\uff0c\u5176\u751f\u6d3b\u6eff\u610f\u5ea6(life satisfaction)\u4ee5\u53ca\u6210\u5c31(achievement)\u6703\u964d\u4f4e\nE. \u6709\u9ad8\u53ef\u4fe1\u5ea6\u4e4b\u8b49\u64da(high level of confidence)\u8b49\u660e\u4f7f\u7528\u5927\u9ebb\u6703\u589e\u52a0\u7f79\u60a3\u80ba\u764c\u7684\u98a8\u96aa\n": "(E)", "103-4.\n\u95dc\u65bc\u6050\u614c\u75c7(panic disorder)\u7684\u6cbb\u7642\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. Benzodiazepine(BZD)\u5efa\u8b70\u53ef\u4ee5\u9577\u671f\u6301\u7e8c\u4f7f\u7528\nB. \u65bc\u6cbb\u7642\u521d\u671f\u53ef\u4ee5\u8003\u616e\u4f75\u7528Selective Serotonin Reuptake Inhibitor(SSRI)\u4ee5\u53caBZD\nC. \u7b49\u5f85\u56db\u9031\u5230\u516d\u9031SSRI\u6548\u679c\u51fa\u4f86\u5f8c\u9010\u6b65\u964d\u4f4eBZD\nD. SSRI\u7684\u8d77\u59cb\u5291\u91cf\u6700\u597d\u5f9eSSRI\u6cbb\u7642\u6182\u9b31\u75c7\u8d77\u59cb\u5291\u91cf\u7684\u3127\u534a\u958b\u59cb\u6295\u85e5\nE. \u75c5\u60a3\u75ca\u7652\u5f8c\u4ecd\u9700\u8981\u3127\u6bb5\u6642\u9593\u7684\u7dad\u6301\u6027(maintenance)\u85e5\u7269\u6cbb\u7642\n": "(A)", "103-5.\n\u4e0b\u5217\u4f55\u8005\u662f\u7f8e\u570b\u7cbe\u795e\u91ab\u5b78\u6703\u7cbe\u795e\u75be\u75c5\u8a3a\u65b7\u53ca\u7d71\u8a08\u624b\u518a\u7b2c\u56db\u7248(DSM-IV)\u5b9a\u7fa9\u300c\u91cd\u5ea6\u6182\u9b31\u767c\u4f5c\u300d(major depresive episode)\u7684\u5178\u578b\u75c7\u72c0\uff1f(1)\u5c0d\u672c\u4f86\u6709\u8208\u8da3\u7684\u4e8b\u7269\u5931\u53bb\u8208\u8da3(anhedonia) (2)\u5bb9\u6613\u75b2\u7d2f(fatigue) (3)\u601d\u8003\u53ca\u52d5\u4f5c\u8b8a\u6162(psychomotor retardation) (4)\u80f8\u60b6(chest tightness) (5)\u5fc3\u60b8(palpitation)\u3002\nA. (1)+(2)+(3)\nB. (1)+(3)+(4)\nC. (2)+(3)+(5)\nD. (1)+(4)+(5)\nE. (3)+(4)+(5)\n": "(A)", "103-6.\n\u4e0b\u5217\u6297\u6182\u9b31\u85e5\u7269\u8207\u526f\u4f5c\u7528\u7684\u914d\u5c0d\uff0c\u54ea\u3127\u7d44\u662f\u4e0d\u5e38\u898b\u7684\uff1f\nA. \u9078\u64c7\u6027\u8840\u6e05\u7d20\u6291\u5236\u5291(Selective Serotonin Reuptake Inhbitor: SSRI)\uff1a\u8178\u80c3\u4e0d\u9069(nausea and other GI effects )\nB. \u4e09\u74b0\u6297\u6182\u9b31\u85e5(Tricyclic antidepressants: TCA):\uff1a\u53e3\u4e7e\u4fbf\u79d8(dry mouth and constipation)\nC. \u9078\u64c7\u6027\u8840\u6e05\u7d20\u6291\u5236\u5291(Selective Serotonin Reuptake Inhibitor: SSRI)\uff1a\u982d\u75db(headache)\nD. \u9078\u64c7\u6027\u65b0\u814e\u4e0a\u817a\u7d20\u8207\u8840\u6e05\u7d20\u518d\u5438\u6536\u6291\u5236\u5291(Selective Norepinephrine/Serotonin Reuptake Inhibitors: SNRI): \u9670\u8396\u7570\u5e38\u52c3\u8d77(priapism)\nE. \u4e09\u74b0\u6297\u6182\u9b31\u85e5(Tricyclic antidepressants: TCA)\uff1a\u9ad4\u91cd\u4e0a\u5347(weight gain)\n": "(D)", "103-7.\n\u5c0d\u65bc\u8b6b\u5984(delirium)\u7684\u8655\u7406\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u591a\u6578\u8b49\u64da\u986f\u793a\u91dd\u5c0d\u8b6b\u5984\u6295\u4e88\u6297\u7cbe\u795e\u75c5\u85e5(antipsychotics)\u6216\u93ae\u5b9a\u5291(sedatives)\u5c0d\u65bc\u5176\u8b6b\u5984\u9810\u5f8c\u6c92\u6709\u6b63\u9762\u5f71\u97ff\nB. \u76ee\u524d\u5c0d\u65bc\u8b6b\u5984\u4e8b\u5148\u9810\u9632(preventive)\u6295\u85e5\u7684\u8af8\u591a\u7814\u7a76\u5747\u986f\u793a\uff1a\u6297\u7cbe\u795e\u75c5\u85e5\u5c0d\u65bc\u9810\u9632\u8b6b\u5984\u767c\u751f\u6709\u986f\u8457\u6548\u679c\nC. \u85e5\u7269\u55ae\u7d14\u5316(drug reduction)\u4e5f\u662f\u8655\u7406\u8b6b\u5984\u7684\u65b9\u6cd5\u4e4b\u3127\nD. \u6297\u7cbe\u795e\u75c5\u85e5\u4ee5\u53ca\u93ae\u5b9a\u5291\u7684\u6295\u4e88\uff0c\u6709\u53ef\u80fd\u5ef6\u9577\u8b6b\u5984\u7684\u75c5\u7a0b\nE. \u907f\u514d\u5c0f\u7761(napping)\u4ee5\u53ca\u589e\u52a0\u767d\u5929\u7167\u5149\u4e5f\u662f\u975e\u85e5\u7269\u6cbb\u7642\u7684\u9078\u9805\n": "(B)", "104-1.\n\u95dc\u65bc\u89aa\u4eba\u904e\u4e16\u4e4b\u5f8c\u54c0\u615f\u53cd\u61c9(grief)\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u6709\u8b49\u64da\u6307\u51fa\u5728\u54c0\u615f\u53cd\u61c9\u7684\u6025\u6027\u671f\u5fc3\u808c\u6897\u585e\u98a8\u96aa\u589e\u52a0\nB. \u5728\u54c0\u615f\u53cd\u61c9\u7684\u6025\u6027\u671f\u8840\u58d3\u5fc3\u8df3\u6703\u589e\u52a0\nC. \u5728\u54c0\u615f\u53cd\u61c9\u7684\u6025\u6027\u671f\u8840\u4e2dcortisol\u6fc3\u5ea6\u964d\u4f4e\nD. \u67092%\u52303%\u5931\u53bb\u89aa\u4eba\u7684\u6c11\u773e\uff0c\u54c0\u615f\u53cd\u61c9\u6301\u7e8c\u592a\u4e45\uff0c\u5f37\u5ea6\u672a\u96a8\u6642\u9593\u6e1b\u5f31\uff0c\u5448\u73fe\u300c\u8907\u96dc\u6027\u300d\u54c0\u615f\u53cd\u61c9(complicated grief)\nE. \u8907\u96dc\u6027\u54c0\u615f\u53cd\u61c9\u9700\u8981\u8ddf\u91cd\u5ea6\u6182\u9b31\u75c7(major depression)\u4ee5\u53ca\u5275\u50b7\u5f8c\u58d3\u529b\u75c7(posttraumatic stress disorder)\u4f5c\u9451\u5225\u8a3a\u65b7\n": "(C)", "104-2.\n\u95dc\u65bc\u8001\u5e74\u6182\u9b31\u75c7(depression in the elderly)\u4e0b\u5217\u4f55\u8005\u932f\u8aa4?\nA. \u7f79\u60a3\u6182\u9b31\u75c7\u6703\u589e\u52a0\u500b\u6848\u7f79\u60a3\u5931\u667a\u75c7\u7684\u98a8\u96aa\nB. \u751f\u6d3b\u4f5c\u606f\u6539\u8b8a(lifestyle changes)\u4e5f\u662f\u6cbb\u7642\u65b9\u5f0f\u4e4b\u4e00\nC. \u4ee5\u751f\u6d3b\u4f5c\u606f\u6539\u8b8a\u4f5c\u70ba\u6cbb\u7642\u65b9\u5f0f\uff0c\u901a\u5e38\u53ef\u4ee5\u55ae\u7368\u9054\u5230\u6cbb\u7642\u6548\u679c\nD. \u85e5\u7269\u6cbb\u7642\u8207\u5fc3\u7406\u6cbb\u7642\u90fd\u53ef\u4ee5\u8003\u616e\u4f5c\u70ba\u7b2c\u4e00\u7dda\u7684\u6cbb\u7642\nE. \u9078\u64c7\u6027\u8840\u6e05\u7d20\u518d\u5438\u6536\u6291\u5236\u5291(selective serotonin reuptake inhibitor: SSRI)\u88ab\u5efa\u8b70\u7576\u4f5c\u85e5\u7269\u6cbb\u7642\u7684\u9996\u9078\n": "(C)", "104-3.\n\u95dc\u65bc\u8a50\u75c5(malingering)\u8207\u5ea0\u75c5\u75c7(factitious disorder)\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u5177\u6709\u300c\u91ab\u7642\u7121\u6cd5\u89e3\u91cb\u7684\u8eab\u9ad4\u75c7\u72c0\u300d(medically unexplained physical symptoms)\u7684\u75c5\u60a3\uff0c\u90fd\u662f\u6709\u7cbe\u795e\u79d1\u8a3a\u65b7\u7684\nB. \u8655\u7406\u5ea0\u75c5\u75c7\u500b\u6848\u7684\u539f\u5247\u5305\u62ec\u300c\u9867\u5168\u500b\u6848\u984f\u9762\u300d(face saving)\u4ee5\u53ca\u300c\u6e1b\u4f4e\u50b7\u5bb3\u300d(harm minimization)\nC. \u9664\u4e86\u91ab\u7642\u4e0a\u8a73\u76e1\u7684\u75c5\u53f2\u8a62\u554f\u8207\u75c5\u6b77\u8cc7\u6599\u56de\u9867\uff0c\u78ba\u8a8d\u8a50\u75c5\u8207\u5ea0\u75c5\u75c7\u4e5f\u9700\u8981\u91ab\u7642\u4ee5\u5916\u7684\u8abf\u67e5\u8cc7\u8a0a(non-medical investigation)\u4f86\u652f\u6301\u8a3a\u65b7\u4e4b\u78ba\u7acb\nD. \u50c5\u4f9d\u9760\u300c\u81e8\u5e8a\u6280\u8853\u300d(clinical skills)\u672c\u8eab\u4e0d\u8db3\u4ee5\u5075\u6e2c(detect)\u6216\u8a3a\u65b7\u8a50\u75c5\nE. \u5373\u4f7f\u6709\u660e\u78ba\u7684\u795e\u7d93\u79d1\u6216\u7cbe\u795e\u79d1\u8a3a\u65b7\u7684\u75c5\u60a3\uff0c\u4ed6\u5011\u7684\u7570\u5e38\u751f\u75c5\u884c\u70ba(abnormal illness behaviors)\uff0c\u4e5f\u4e26\u975e\u5b8c\u5168\u6e90\u81ea\u65bc\u4ed6\u5011\u7f79\u60a3\u7684\u75be\u75c5\u672c\u8eab\n": "(A)", "104-4.\n\u95dc\u65bc\u8001\u5e74\u4eba\u7684\u8b6b\u5984(delirium)\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u6c92\u6709\u8db3\u5920\u7684\u8b49\u64da\u8b49\u660e\u6295\u4e88\u85e5\u7269\u53ef\u4ee5\u6709\u6548\u5730\u300c\u9810\u9632\u300d\u8b6b\u5984\u767c\u751f\nB. \u5728\u4e00\u822c\u91ab\u7642\u60c5\u5883(general medicine)\u7576\u4e2d\uff0c\u6182\u9b31\u75c7(depression)\u66fe\u7d93\u88ab\u8b49\u660e\u662f\u8b6b\u5984\u7684\u5371\u96aa\u56e0\u5b50\u4e4b\u4e00\nC. Serum urea \u589e\u52a0\u4e5f\u662f\u8b6b\u5984\u7684\u5371\u96aa\u56e0\u5b50\u4e4b\u4e00\nD. \u8166\u6ce2\u6aa2\u67e5 (electroencephalography: EEG)\u5c0d\u65bc\u8a3a\u65b7\u8b6b\u5984\uff0c\u6709\u826f\u597d\u7684\u654f\u611f\u5ea6(sensitivity)\u53ca\u7279\u7570\u5ea6(specificity)\nE. Haloperidol 0.5mg BID \u662f\u5408\u7406\u7684\u85e5\u7269\u6cbb\u7642\u9078\u64c7\n": "(D)", "104-5.\n\u4e0b\u5217\u5408\u8005\u975e\u6050\u614c\u767c\u4f5c(panic attack)\u7684\u5178\u578b\u75c7\u72c0\uff1f\nA. \u5fc3\u60b8 (palpitation)\nB. \u80f8\u75db (chest pain)\nC. \u5bb3\u6015\u81ea\u5df1\u5feb\u8981\u6b7b\u6389 (fear of dying)\nD. \u7570\u7269\u6897\u585e\u611f (feeling of choking)\nE. \u6613\u6012\u60c5\u7dd2 (irritable mood)\n": "(E)", "104-6.\n\u95dc\u65bc\u6297\u6182\u9b31\u85e5\u7269\u526f\u4f5c\u7528\u7684\u8655\u7406\u65b9\u5f0f\uff0c\u4e0b\u5217\u5408\u8005\u70ba\u975e\uff1f\nA. \u5641\u5fc3 (nausea)\uff1a\u6301\u7e8c\u5f88\u4e45\u4e14\u8207\u5291\u91cf\u7121\u95dc\uff0c\u53ef\u4f75\u7528\u5236\u9178\u5291\u5e6b\u52a9\u7de9\u89e3\u6216\u96a8\u9910\u670d\u7528\nB. \u6027\u9ad8\u6f6e\u4e0d\u80fd (anorgasmia)\uff1a\u4f7f\u7528cyproheptadine 4mg to 8mg \u65bc\u6027\u6d3b\u52d5\u524d2\u5c0f\u6642\u670d\u7528\nC. \u9ad4\u91cd\u4e0a\u5347 (weight gain)\uff1a\u904b\u52d5\u7bc0\u98df\u6216\u8003\u616e\u6539\u70ba fluoxetine\nD. \u59ff\u52e2\u6027\u4f4e\u8840\u58d3 (orthostatic hypotension)\uff1a\u4e0d\u5bb9\u6613\u7522\u751f\u8010\u53d7\u6027\u800c\u81ea\u7136\u7de9\u89e3\uff0c\u589e\u52a0\u98f2\u6c34\u91cf\uff0c\u6216\u662f\u4f7f\u7528 fludrocortisone 0.025mg/day\nE. \u6297\u4e59\u91af\u81bd\u9e7c(anticholinergic)\u526f\u4f5c\u7528\uff1a\u7b49\u5f85\u8010\u53d7\u6027\u7522\u751f (wait for tolerance)\n": "(A)", "104-7.\n\u95dc\u65bc\u6cbb\u7642\u96d9\u6975\u6027\u60c5\u611f\u75be\u60a3(bipolar affective disorder)\u7684\u60c5\u7dd2\u7a69\u5b9a\u5291(mood stabilizer)\u7684\u7279\u6027\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u662f\uff1f(1) \u92f0\u9e7d(lithium)\u7684\u6709\u6548\u8840\u4e2d\u6cbb\u7642\u6fc3\u5ea6\u7bc4\u570d\u70ba 8-12 meq/L\uff1b(2) Thiazide\u6703\u6e1b\u5c11\u92f0\u9e7d\u7684\u8840\u4e2d\u6fc3\u5ea6\uff1b(3) Valproic acid\u7684\u6709\u6548\u8840\u4e2d\u6cbb\u7642\u6fc3\u5ea6\u70ba50-125 ug/ml\uff1b(4) \u80f0\u81df\u708e(pancreatitis)\u662fValproic acid\u53ef\u80fd\u7684\u7f55\u898b\u526f\u4f5c\u7528\u4e4b\u4e00\uff1b(5) Lamotrigine\u7684\u7f55\u898b\u526f\u4f5c\u7528\u5305\u62ecStevens-Johnson syndrome\nA. (1)+(2)+(3)\nB. (1)+(3)+(5)\nC. (2)+(3)+(4)\nD. (1)+(2)+(5)\nE. (3)+(4)+(5)\n": "(E)", "105-1.\n\u95dc\u65bc\u81ea\u6bba\u9632\u6cbb\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u5404\u7a2e\u7528\u65bc\u9810\u6e2c\u81ea\u6bba\u98a8\u96aa\u7684\u7be9\u6aa2\u554f\u5377\uff0c\u5c0d\u65bc\u672a\u4f86\u81ea\u6bba\u884c\u70ba\u7684\u967d\u6027\u9810\u6e2c\u7387 (positive predictive value) \u90fd\u4e0d\u9ad8\uff0c\u5f88\u5c11\u8d85\u904e20%\nB. \u66fe\u7d93\u56e0\u70ba\u81ea\u6211\u50b7\u5bb3(self-harm)\u4f86\u6025\u8a3a\u7684\u6c11\u773e\uff0c\u5927\u7d042%\u5728\u672a\u4f86\u4e00\u5e74\u6703\u6b7b\u65bc\u81ea\u6bba\nC. \u66fe\u6709\u7814\u7a76\u6307\u51fa\uff0c\u4e0d\u5e78\u81ea\u6bba\u8eab\u4ea1\u7684\u500b\u6848\u4e2d\uff0c\u670980%\u5728\u4ed6\u5011\u6700\u5f8c\u7684\u8a9e\u8a00\u6e9d\u901a\u4e2d\uff0c\u672a\u66fe\u986f\u9732\u81ea\u6bba\u7684\u610f\u5ff5\u60f3\u6cd5\nD. \u5be6\u8b49\u7814\u7a76\u5747\u986f\u793a\uff1a\u8a62\u554f\u75c5\u60a3\u662f\u5426\u6709\u81ea\u6bba\u610f\u5ff5\uff0c\u6703\u5927\u5e45\u589e\u52a0\u75c5\u60a3\u81ea\u6bba\u98a8\u96aa\nE. \u75c5\u4eba\u5f9e\u7cbe\u795e\u79d1\u75c5\u623f\u51fa\u9662\u5f8c\u4e00\u9031\u5167\u662f\u81ea\u6bba\u7684\u9ad8\u98a8\u96aa\u6642\u6bb5\n": "(D)", "105-2.\n\u95dc\u65bc\u4e0b\u5217\u5404\u7a2e\u6297\u7126\u616e\u85e5\u7269\u7684\u7279\u6027\u63cf\u8ff0\u4f55\u8005\u70ba\u975e\uff1f\nA. Diazepam\u4f5c\u7528\u901f\u5ea6(action of onset)\u5feb\uff0c\u93ae\u975c(sedation)\u6548\u679c\u660e\u986f\nB. Lorazepam\u4f5c\u7528\u901f\u5ea6\u4e2d\u7b49\uff0c\u7121\u6d3b\u6027\u4ee3\u8b1d\u7269(no active metabolites)\nC. Alprazolam\u4f5c\u7528\u901f\u5ea6\u4e2d\u7b49\uff0c\u8f03\u96e3\u6212\u65b7\u505c\u85e5(difficult to withdrawal)\nD. Oxazepam\u4f5c\u7528\u901f\u5ea6\u5feb\uff0c\u5177\u6709\u534a\u8870\u671f\u6975\u9577\u4e4b\u6d3b\u6027\u4ee3\u8b1d\u7269\nE. Clonazepam\u4f5c\u7528\u901f\u5ea6\u6162\uff0c\u7f8e\u570bFDA\u6838\u51c6\u4f7f\u7528\u65bc\u6050\u614c\u75c7(panic disorder)\n": "(D)", "105-3.\n\u95dc\u65bc\u9d09\u7247\u985e(opioid)\u88fd\u5291\u904e\u91cf(overdose)\u7684\u8655\u7f6e\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u7dad\u8b77\u6c23\u9053(establish airway)\u70ba\u9996\u8981\uff0c\u6709\u6642\u9700\u8981\u63d2\u7ba1\u6216\u4f7f\u7528\u547c\u5438\u5668\nB. Naloxone\u4e00\u822c\u5efa\u8b70\u5291\u91cf0.4mg-2.0mg\uff0c\u53ef\u85c9\u7531\u808c\u8089\u6ce8\u5c04\uff0c\u975c\u8108\u6ce8\u5c04\uff0c\u6216\u662f\u6c23\u7ba1\u5167\u7ba1(endotracheal tube)\u7d66\u85e5\nC. Naloxone\u975c\u8108\u7d66\u85e5\u5f8c10\u81f320\u5206\u9418\u898b\u6548\nD. \u82e5\u547c\u5438\u4ecd\u4e0d\u7406\u60f3Naloxone\u9700\u91cd\u8907\u7d66\u85e5\nE. \u7576\u547c\u5438\u6291\u5236\u89e3\u9664\u5f8c\uff0c\u6bcf\u5c0f\u6642\u6295\u8207\u8d77\u59cb\u5291\u91cf\u76841/2\u52302/3\u505a\u70ba\u7dad\u6301\u6cbb\u7642\n": "(C)", "105-4.\n\u95dc\u65bc\u7f8e\u570b\u7cbe\u795e\u91ab\u5b78\u6703\u9812\u5e03\u300c\u7cbe\u795e\u75be\u75c5\u8a3a\u65b7\u7d71\u8a08\u624b\u518a\u7b2c\u4e94\u7248\u300d(Diagnostic and Statistical Manual of Mental DIsorders, Fifth edition: DSM-5)\uff0c\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u9152\u7cbe\u4f7f\u7528\u75be\u60a3(alcohol use disorder)\u7684\u8a3a\u65b7\u5167\u5bb9\nA. \u9152\u7cbe\u7684\u8010\u53d7\u6027(tolerance)\nB. \u6e34\u671b\u98f2\u9152(alcohol craving)\nC. \u559d\u5f97\u6bd4\u9810\u671f\u7684\u9084\u591a\u9084\u4e45(larger amount or longer)\nD. \u53cd\u8986\u60f3\u6212\u9152\u4f46\u6212\u4e0d\u6389\nE. \u98f2\u9152\u5f8c\u7522\u751f\u91cd\u5ea6\u6182\u9b31\u767c\u4f5c\n": "(E)", "105-5.\n\u95dc\u65bc\u5931\u7720\u500b\u6848\u7684\u975e\u85e5\u7269\u8655\u7f6e\u885b\u6559\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u523a\u6fc0\u63a7\u5236(stimulus control)\uff1a\u6709\u7761\u610f\u7684\u6642\u5019\u624d\u53bb\u5e8a\u4e0a\u7761\uff0c\u7761\u4e0d\u8457\u800c\u4e14\u7126\u616e\u7684\u6642\u5019\u5c31\u96e2\u958b\u5e8a\u8216\nB. \u7761\u7720\u885b\u751f(sleep hygiene)\uff1a\u81e5\u5ba4\u5b9c\u6697\u800c\u5b89\u975c\uff0c\u6642\u9418\u5b9c\u79fb\u9664\u65bc\u8996\u7dda\u7bc4\u570d\u5916\nC. \u653e\u9b06\u6cbb\u7642(relaxation therapy)\uff1a\u808c\u8089\u653e\u9b06\uff0c\u547c\u5438\u8a13\u7df4\uff0c\u6c89\u601d\u51a5\u60f3(meditation)\nD. \u8a8d\u77e5\u6cbb\u7642(cognitive therapy)\uff1a\u7dad\u6301\u5c0d\u65bc\u7761\u7720\u7684\u5408\u7406\u671f\u5f85\uff0c\u6311\u6230\u64d4\u5fc3\u5931\u7720\u6703\u5f15\u767c\u707d\u96e3\u6027\u7684\u904e\u5ea6\u9810\u671f\u5fc3\u614b\nE. \u9650\u5236\u7761\u7720(sleep restriction)\uff1a\u6e1b\u5c11\u8eba\u5e8a\u6642\u9593\u81f33\u500b\u5c0f\u6642\uff0c\u4e26\u4e14\u8207\u500b\u6848\u7684\u751f\u7269\u9031\u671f(circadian rhythm)\u53cd\u5411\u64cd\u4f5c\n": "(E)", "105-6.\n\u95dc\u65bc\u8001\u4eba\u8650\u5f85(elder abuse)\u5728\u81e8\u5e8a\u4e0a\u53ef\u80fd\u7684\u7dda\u7d22\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u4e00\u822c\u8001\u5e74\u4eba\u8eab\u4e0a\u9bae\u5c11\u6709\u81ea\u767c\u6027\u7684\u7600\u9752(bruise)\nB. \u8001\u5e74\u4eba\u56e0\u8dcc\u5012\u800c\u9020\u6210\u982d\u90e8\u7684\u9aa8\u6298\u8f03\u5e38\u898b\u65bc\u773c\u7aa9(orbital)\u9aa8\u53ca\u9f3b\u6a11\u9aa8(nasal)\uff0c\u56e0\u70ba\u8650\u5f85\u6bc6\u6253\u8f03\u5e38\u898b\u65bc\u4e0b\u984e(jaw)\u4ee5\u53ca\u9874\u9aa8(zygomatic)\u9aa8\u6298\nC. \u88ab\u8eab\u9ad4\u8650\u5f85(physical abuse)\u7684\u8001\u4eba\uff0c\u8eab\u4e0a\u53ef\u80fd\u6709\u8a31\u591a\u50b7\u53e3\uff0c\u800c\u4e14\u8655\u5728\u4e0d\u540c\u7684\u7652\u5408\u968e\u6bb5\nD. \u5fc3\u7406\u8650\u5f85(psychological abuse)\u7684\u8de1\u8c61\u5305\u62ec\u8001\u4eba\u88ab\u523b\u610f\u9694\u7d55\u65bc\u8ddf\u597d\u670b\u53cb\u6216\u4fe1\u8cf4\u5bb6\u4eba\u7684\u4e92\u52d5\u63a5\u89f8\nE. \u5e38\u7167\u6a5f\u69cb\u5167\u7684\u8001\u4eba\u8650\u5f85\u50b7\u5bb3\uff0c\u6709\u53ef\u80fd\u662f\u6a5f\u69cb\u4f4f\u6c11\u9593\u4e92\u76f8\u653b\u64ca\u6240\u81f4\n": "(A)", "105-7.\n\u95dc\u65bc\u91cd\u5ea6\u6182\u9b31\u75c7\u7684\u8a3a\u65b7\u8207\u6cbb\u7642\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u8d77\u59cb\u968e\u6bb5\u4e3b\u8981\u662f\u75c5\u4eba\u885b\u6559\u4ee5\u53ca\u9078\u7528\u53ef\u8010\u53d7\u7684\u85e5\u7269\nB. \u82e5\u6297\u6182\u9b31\u85e5\u7269\u6cbb\u7642\u53cd\u61c9\u4e0d\u4f73\uff0c\u9700\u8003\u616e\u500b\u6848\u4e4b\u9451\u5225\u8a3a\u65b7\u662f\u5426\u70ba\u96d9\u6975\u6027\u60c5\u611f\u75be\u60a3\nC. \u5c0d\u65bcSSRI\u6cbb\u7642\u53cd\u61c9\u4e0d\u4f73(treatment resistant)\u7684\u91cd\u5ea6\u6182\u9b31\u75c7\u500b\u6848\uff0c\u63db\u6210SNRI\u7684\u9810\u671f\u7642\u6548(efficacy)\uff0c\u6bd4\u63db\u6210mirtazapine\u7684\u9810\u671f\u7642\u6548\u986f\u8457\u70ba\u9ad8\nD. \u6cbb\u7642\u91cd\u5ea6\u6182\u9b31\u75c7\u500b\u6848\u82e5\u6c92\u6709\u9054\u5230\u5b8c\u5168\u7de9\u89e3(full remission)\uff0c\u5fa9\u767c\u98a8\u96aa\u589e\u52a0\uff0c\u81ea\u6bba\u98a8\u96aa\u4e5f\u589e\u9ad8\nE. \u9078\u7528\u85e5\u7269\u7684\u53c3\u8003\u4f9d\u64da\uff0c\u9084\u5305\u62ec\u500b\u6848\u89aa\u4eba\u82e5\u4e5f\u6709\u91cd\u5ea6\u6182\u9b31\u75c7\uff0c\u5176\u89aa\u4eba\u7684\u85e5\u7269\u6cbb\u7642\u53cd\u61c9\n": "(C)", "106-1.\n\u4e0b\u5217\u95dc\u65bc\u81ea\u6bba\u7684\u63cf\u8ff0\u4f55\u8005\u70ba\u975e\uff1f\nA. \u8eab\u9ad4\u75be\u75c5\u5982\u51a0\u72c0\u52d5\u8108\u5fc3\u81df\u75c5\u53ca\u6162\u6027\u963b\u585e\u6027\u80ba\u75be\u60a3\uff0c\u82e5\u5408\u4f75\u6182\u9b31\u75c7\uff0c\u6703\u589e\u52a0\u81ea\u6bba\u7684\u98a8\u96aa\nB. \u6709\u4e9b\u6162\u6027\u75be\u75c5\u5982\u7672\u7647\u4ee5\u53ca\u767c\u708e\u6027\u8178\u9053\u75be\u75c5 (inflammatory bowel disease)\uff0c\u672c\u8eab\u4e0d\u9700\u8981\u5408\u4f75\u7cbe\u795e\u75be\u75c5\uff0c\u81ea\u6bba\u98a8\u96aa\u5c31\u589e\u52a0\nC. \u5931\u7720\u672c\u8eab\u662f\u81ea\u6bba\u7368\u7acb\u7684\u5371\u96aa\u56e0\u5b50\uff0c\u5176\u6a5f\u8f49\u53ef\u80fd\u900f\u904e\u5931\u7720\u589e\u52a0\u885d\u52d5\u6027\u4ee5\u53ca\u8a8d\u77e5\u7684\u504f\u5dee\nD. \u5275\u50b7\u6027\u8166\u50b7 (traumatic brain injury) \u4e0d\u6703\u589e\u52a0\u81ea\u6bba\u98a8\u96aa\nE. \u591a\u767c\u6027\u786c\u5316\u75c7\u4e5f\u6703\u589e\u52a0\u81ea\u6bba\u98a8\u96aa\n": "(D)", "106-2.\n\u95dc\u65bcbenzodiazepine (BZD) \u985e\u85e5\u7269\u7684\u6210\u766e\u554f\u984c\u53ca\u6212\u6cbb\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. BZD\u7684\u4f9d\u8cf4\u6027(dependence)\u53ef\u4ee5\u767c\u751f\u5728\u4f4e\u5291\u91cf\u800c\u4e14\u6c92\u6709\u7522\u751f\u8010\u53d7\u6027(tolerance)\u7684\u60c5\u6cc1\u4e0b\nB. BZD\u7684\u6212\u65b7\u75c7\u72c0\uff0c\u9577\u6548\u578b\u7684\u85e5\u7269\u767c\u751f\u5728\u65b7\u85e5\u5f8c5-10\u5929\uff0c\u77ed\u6548\u7684\u85e5\u7269\u5927\u7d04\u57282-3\u5929\nC. \u6bcf\u65e5\u4f7f\u7528BZD\u7576\u91cf\u82e5\u8d85\u904e100 mg\u7684diazepam\uff0c\u5efa\u8b70\u4f4f\u9662\u4f86\u6212\u85e5\nD. \u5354\u52a9\u4f7f\u7528\u591a\u7a2eBZD\u500b\u6848\u6212\u85e5\u6642\uff0c\u61c9\u5148\u5c07BZD\u7a2e\u985e\u55ae\u7d14\u5316\u81f3diazepam\u4e00\u7a2e\nE. \u4f9d\u64da\u5be6\u8b49\u91ab\u5b78\u56de\u9867\u7684\u5171\u8b58\uff0c\u6212\u9664\u5927\u65bc30 mg diazepam\u7684BZD\u6210\u766e\uff0c\u53ef\u57284-6\u5929\u5b8c\u6210\n": "(E)", "106-3.\n\u95dc\u65bc\u6182\u9b31\u75c7\u7be9\u6aa2\u8207\u6cbb\u7642\u7684\u6700\u65b0\u5efa\u8b70\uff0c\u4e0b\u5217\u4f55\u8005\u662f\u6b63\u78ba\u7684\uff1f(1)\u5b55\u7522\u671f\u5a66\u5973(pregnant and postpartum)\u4e0d\u61c9\u8a72\u7d0d\u5165\u7be9\u6aa2\uff1b(2)\u9577\u671f\u5931\u7720\u4e5f\u662f\u9020\u6210\u8001\u5e74\u4eba\u6182\u9b31\u7684\u5371\u96aa\u56e0\u5b50\uff1b(3)\u5c0d\u65bc\u6210\u4eba\u6182\u9b31\u75c7\u7684\u6cbb\u7642\uff0c\u8207\u5b89\u6170\u5291\u76f8\u8f03\uff0c\u76ee\u524d\u4e26\u7121\u7814\u7a76\u8b49\u5be6\u6297\u6182\u9b31\u85e5\u7269\u5728\u7d71\u8a08\u4e0a\u986f\u8457\u5730\u589e\u52a0\u81ea\u6bba\u6b7b\u4ea1\u98a8\u96aa\uff1b(4)\u8a8d\u77e5\u884c\u70ba\u6cbb\u7642(cognitive behavioral psychotherapy)\u88ab\u8b49\u5be6\u5c0d\u65bc\u9810\u7522\u671f\u5a66\u5973\u7684\u6182\u9b31\u75c7\u6c92\u6709\u7642\u6548\uff1b(5)\u9762\u5c0d\u56f0\u96e3\u990a\u80b2\u5f88\u96e3\u5e36\u7684\u5b30\u5152(difficult infant temperament)\uff0c\u4e5f\u662f\u7522\u5f8c\u6182\u9b31\u7684\u5371\u96aa\u56e0\u5b50\u3002\nA. (2)+(3)+(5)\nB. (1)+(4)+(5)\nC. (1)+(2)+(3)\nD. (2)+(3)+(4)\nE. (1)+(3)+(5)\n": "(A)", "106-4.\n\u95dc\u65bc\u7126\u616e\u75be\u60a3(anxiety disorders)\u7684\u6cbb\u7642\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u76ee\u524d\u6c92\u6709\u8db3\u5920\u8b49\u64da\u652f\u6301\u8981\u4ee5\u85e5\u7269\u6cbb\u7642\u6216\u5fc3\u7406\u6cbb\u7642\uff0c\u4f5c\u70ba\u9996\u9078\u6cbb\u7642\u65b9\u5f0f\nB. Inderal \u53ef\u4ee5\u6e1b\u8f15\u793e\u4ea4\u7126\u616e\u75c7(social anxiety disorder)\u7684\u75c7\u72c0\nC. Benzodiazepine\u985e\u85e5\u7269\u53ef\u4ee5\u4f5c\u70ba\u7b2c\u4e00\u7dda\u7684\u55ae\u7368\u6cbb\u7642(monotherapy)\u9078\u9805\nD. \u7528\u9078\u64c7\u6027\u8840\u6e05\u7d20\u518d\u5438\u6536\u6291\u5236\u5291(SSRI)\u6cbb\u7642\u7126\u616e\u75be\u60a3\uff0c\u8d77\u59cb\u5291\u91cf\u5efa\u8b70\u7531SSRI\u6cbb\u7642\u6182\u9b31\u75c7\u8d77\u59cb\u5291\u91cf\u7684\u4e00\u534a\u958b\u59cb\nE. \u7576\u7126\u616e\u75be\u60a3\u7528\u85e5\u7269\u6cbb\u7652\u5f8c\uff0c\u9084\u9700\u8981\u85e5\u7269\u505a\u7dad\u6301\u6027\u6cbb\u7642\u4e00\u6bb5\u6642\u9593\n": "(C)", "106-5.\n\u95dc\u65bc\u6050\u614c\u75c7\u7684\u63cf\u8ff0\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u662f\u6c11\u773e\u5c0b\u6c42\u5167\u79d1\u91ab\u5e2b\u8a3a\u6cbb\u7684\u5e38\u898b\u539f\u56e0\u4e4b\u4e00\nB. \u81e8\u5e8a\u8868\u73fe\u70ba\u53cd\u8986\u4e14\u4e0d\u53ef\u9810\u671f\u7684\u7126\u616e\u75c7\u72c0\u767c\u4f5c\nC. \u7406\u5b78\u8207\u5be6\u9a57\u5ba4\u6aa2\u67e5\u7d50\u679c\u6703\u767c\u73fe\u80fd\u89e3\u91cb\u767c\u4f5c\u75c7\u72c0\u4e4b\u539f\u56e0\nD. \u500b\u6848\u6703\u5bb3\u6015\u4e0b\u4e00\u6b21\u767c\u4f5c\uff0c\u6216\u56e0\u5bb3\u6015\u767c\u4f5c\u800c\u81ea\u6211\u9650\u5236\u6d3b\u52d5\u7bc4\u570d\nE. \u7532\u72c0\u817a\u529f\u80fd\u7570\u5e38\u662f\u9451\u5225\u8a3a\u65b7\u4e4b\u4e00\n": "(C)", "106-6.\n\u95dc\u65bc\u5f37\u8feb\u75c7(obsessive-compulsive disorder: OCD)\u7684\u8a3a\u65b7\u8207\u6cbb\u7642\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u500b\u6848\u53ef\u80fd\u6703\u6301\u7e8c\u61f7\u7591(persistent doubting)\u5927\u9580\u6709\u6c92\u6709\u9396\u597d\uff0c\u800c\u53cd\u8986\u6aa2\u67e5\u9580\u9396\nB. \u500b\u6848\u53ef\u80fd\u6703\u5bb3\u6015\u81ea\u5df1\u4e0d\u5c0f\u5fc3\u9020\u6210\u50b7\u5bb3(fear of causing harm)\uff0c\u800c\u91cd\u8907\u6298\u8fd4\u525b\u525b\u958b\u8eca\u7d93\u904e\u7684\u8def\u6bb5\u6aa2\u67e5\nC. \u91dd\u5c0dOCD\u4f7f\u7528\u85e5\u7269\u6cbb\u7642\u7684\u7642\u6548\uff0c\u7d9c\u5408\u5206\u6790\u5448\u73fe\uff1a\u9700\u6cbb\u4eba\u6578(number needed to treat: NNT)\u5927\u7d045\nD. \u91dd\u5c0dOCD\u4f7f\u7528\u5fc3\u7406\u6cbb\u7642(psychotherapy)\u7684\u7642\u6548\uff0c\u7d9c\u5408\u5206\u6790\u5448\u73feNNT\u5927\u65bc10\nE. \u82e5\u4ee5clomipramine\u6cbb\u7642OCD\uff0c\u6bcf\u65e5\u76ee\u6a19\u5291\u91cf\u70ba250 mg\n": "(D)", "106-7.\n\u95dc\u65bc\u8207\u56b4\u91cd\u81f4\u547d\u6027\u75be\u75c5(serious and life-threatening illness)\u75c5\u60a3\u4e4b\u9593\u7684\u91ab\u75c5\u6e9d\u901a\u7b56\u7565\u8207\u77e5\u80fd\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u963b\u7919\u9019\u985e\u6e9d\u901a\u7684\u539f\u56e0\u4e4b\u4e00\u662f\u75c5\u60a3\u8207\u91ab\u5e2b\u90fd\u7b49\u5f85\u5c0d\u65b9\u5148\u958b\u555f\u9019\u985e\u8a71\u984c\nB. \u91ab\u5e2b\u5728\u9810\u5f8c\u63a8\u6e2c(prognostication)\u7684\u6559\u80b2\u8a13\u7df4\u5145\u8db3\u8207\u5426\uff0c\u4e5f\u662f\u963b\u7919\u6b64\u985e\u6e9d\u901a\u7684\u539f\u56e0\nC. \u7167\u8b77\u9ad4\u7cfb\u5206\u5de5\u592a\u7d30\u7f3a\u4e4f\u5354\u8abf(lack of coordination)\u4e5f\u662f\u5f71\u97ff\u9019\u985e\u6e9d\u901a\u6548\u80fd\u7684\u539f\u56e0\u4e4b\u4e00\nD. \u900f\u904e\u6559\u80b2\u8a13\u7df4\u5efa\u7acb\u77e5\u8b58(knowlege)\u3001\u614b\u5ea6(attitude)\u8207\u6280\u5de7(skill)\u7684\u9023\u7d50\uff0c\u6709\u52a9\u65bc\u589e\u9032\u751f\u547d\u672b\u671f(end-of-life)\u7684\u91ab\u75c5\u6e9d\u901a\u54c1\u8cea\nE. \u5c0d\u91ab\u5e2b\u5c08\u696d\u800c\u8a00\uff0c\u9762\u5c0d\u56b4\u91cd\u81f4\u547d\u75be\u75c5\u7684\u91ab\u75c5\u6e9d\u901a\uff0c\u662f\u4e0d\u6703\u6709\u58d3\u529b\u7684\n": "(E)", "107-1.\n\u95dc\u65bc\u8001\u5e74\u8b6b\u5984(delirium)\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u5728\u6025\u8a3a\u5c31\u91ab\u7684\u8001\u5e74\u4eba\u767c\u751f\u8b6b\u5984\u7684\u6a5f\u6703\u53ef\u905410%-15%\nB. \u4f4e\u6d3b\u52d5\u5ea6(hypoactive)\u8b6b\u5984\u500b\u6848\u9810\u5f8c\u8f03\u4f73\nC. \u7537\u6027\u8001\u5e74\u75c5\u60a3\u6bd4\u5973\u6027\u8001\u5e74\u75c5\u60a3\u5bb9\u6613\u767c\u751f\u8b6b\u5984\nD. \u6025\u6027\u767c\u751f\u6ce8\u610f\u529b(attention)\u8207\u5c0d\u5468\u906d\u611f\u77e5(awareness)\u7684\u969c\u7919\u662f\u5176\u7279\u5fb5\nE. \u8b6b\u5984\u75c5\u7a0b\u6709\u6642\u5019\u6703\u6301\u7e8c\u5230\u51fa\u9662\u751a\u81f3\u9577\u9054\u4e00\u500b\u6708\n": "(B)", "107-2.\n\u95dc\u65bc\u8001\u5e74\u8b6b\u5984(delirium)\u7684\u85e5\u7269\u6cbb\u7642\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. Haloperidol \u8d77\u59cb\u5291\u91cf 0.25-0.5mg\uff0c\u6bcf\u65e5\u6700\u9ad8\u5efa\u8b70\u5291\u91cf 30mg\uff0c\u662f\u4f7f\u7528\u7d93\u9a57\u6700\u4e45\u7684\u85e5\u7269\u4e4b\u4e00\nB. Ziprasidone \u8d77\u59cb\u5291\u91cf 5-10mg\uff0c\u6bcf\u65e5\u6700\u9ad8\u5efa\u8b70\u5291\u91cf 40mg\uff0c\u4e3b\u8981\u5728ICU\u5167\u4f7f\u7528\nC. Olanzapine \u8d77\u59cb\u5291\u91cf 2.5-5mg\uff0c\u6bcf\u65e5\u6700\u9ad8\u5efa\u8b70\u5291\u91cf 20mg\uff0c\u5c0d\u65bc\u6025\u6027\u75c7\u72c0\u7642\u6548\u53e3\u670d\u4f4e\u65bc\u808c\u8089\u6ce8\u5c04\nD. Lorazepam \u8d77\u59cb\u5291\u91cf 0.25-0.5mg\uff0c\u6bcf\u65e5\u6700\u9ad8\u5291\u91cf 2mg\uff0c\u662f\u7b2c\u4e8c\u7dda\u7684\u9078\u64c7\nE. Quetiapine \u8d77\u59cb\u5291\u91cf 12.5-25mg\uff0c\u6bcf\u65e5\u6700\u9ad8\u5291\u91cf 50mg\uff0c\u9808\u6ce8\u610f\u4f4e\u8840\u58d3\u554f\u984c\n": "(A)", "107-3.\n\u95dc\u65bc\u7cbe\u795e\u75c5(psychotic disorder)\uff0c\u4e5f\u5c31\u662f\u5305\u62ec\u601d\u89ba\u5931\u8abf\u75c7(schizophrenia)\u8207\u5984\u60f3\u75c7(delusional disorder)\u7b49\u56b4\u91cd\u7684\u7cbe\u795e\u75be\u75c5\u7684\u63cf\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u591a\u5df4\u80fa\u7b2c\u4e8c\u578b\u53d7\u9ad4\u963b\u65b7\u5291\u662f\u5e38\u7528\u7684\u6cbb\u7642\u85e5\u7269\nB. \u96fb\u7642(ECT)\u5c0d\u65bc\u5408\u4f75\u50f5\u76f4\u72c0\u614b\u6216\u6709\u660e\u986f\u60c5\u611f\u75c7\u72c0\u8005\u7642\u6548\u8f03\u4f73\nC. \u53ea\u6709\u4e0d\u5230\u4e00\u6210\u4ee5\u4e0b\u7684\u7cbe\u795e\u75c5(psychotic disorder)\u500b\u6848\u66fe\u7d93\u4f01\u5716\u81ea\u6bba\nD. \u7cbe\u795e\u75c5(psychotic disorder)\u500b\u6848\u5bb9\u6613\u6210\u70ba\u53d7\u5bb3\u8005(victimization by others)\nE. \u7cbe\u795e\u75c5(psychotic disorder)\u66fe\u88ab\u8b49\u660e\u662f\u66b4\u529b\u884c\u70ba(acts of violence)\u7684\u5371\u96aa\u56e0\u5b50\n": "(C)", "107-4.\n\u95dc\u65bc\u81ea\u9589\u75c7\u6216\u6cdb\u81ea\u9589\u75c7\u969c\u7919(autism spectrum disorder, ASD)\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u4e9e\u65af\u4f2f\u683c\u75c7(Asperger's disorder)\u5c6c\u65bc\u5176\u4e2d\u7684\u4e00\u500b\u578b\u614b\nB. \u793e\u6703\u4eba\u969b\u6e9d\u901a\u80fd\u529b\u591a\u9762\u5411\u6301\u7e8c\u7684\u7f3a\u640d\u662f\u5176\u7279\u5fb5\nC. \u500b\u6848\u5448\u73fe\u4fb7\u9650\u800c\u91cd\u8907\u7684\u884c\u70ba\u6a21\u5f0f\u8207\u8208\u8da3\nD. \u6ce8\u610f\u529b\u4e0d\u8db3\u904e\u52d5\u75c7(ADHD)\u5f88\u5c11\u8207ASD\u5171\u75c5\nE. \u6559\u5c0e\u96d9\u89aa\u5982\u4f55\u8207ASD\u7684\u5b69\u5b50\u4e92\u52d5\uff0c\u88ab\u8b49\u660e\u53ef\u5feb\u901f\u6539\u5584\u5b69\u7ae5\u7684\u793e\u6703\u884c\u70ba\u8207\u6e9d\u901a\n": "(D)", "107-5.\n\u95dc\u65bc\u5275\u50b7\u5f8c\u58d3\u529b\u75c7(post-traumatic stress disorder, PTSD)\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u81e8\u5e8a\u75c7\u72c0\u4e0a\u5305\u62ec\u91cd\u8907\u51fa\u73fe\u8207\u5275\u50b7\u4e8b\u4ef6\u76f8\u95dc\u7684\u5669\u5922\nB. \u7121\u6545\u6216\u56e0\u7d30\u6545\u6613\u6012(irritable behavior)\u751a\u81f3\u5bb9\u6613\u66b4\u6012(anger outbursts)\u4e5f\u662f\u53ef\u80fd\u7684\u75c7\u72c0\u4e4b\u4e00\nC. Sertraline\u4ee5\u53caparoxetine\u662f\u7f8e\u570bFDA\u6838\u51c6\u7684\u6cbb\u7642\u7528\u85e5\nD. \u7dad\u6301\u6027\u85e5\u7269\u6cbb\u7642\u9700\u90546\u81f312\u500b\u6708\uff0c\u800c\u4e14\u7de9\u6162\u5730\u6e1b\u91cf\uff0c\u4ee5\u9632\u5fa9\u767c\nE. PTSD\u4e0d\u6703\u5728\u5275\u50b7\u4e8b\u4ef6\u767c\u751f\u5f8c\u4e00\u6bb5\u6642\u9593\u624d\u5ef6\u9072\u767c\u751f(delayed expression)\n": "(E)", "107-6.\n\u95dc\u65bc\u5b89\u7720\u85e5\u7269(hypnotics)\u4e0b\u5217\u4f55\u8005\u932f\u8aa4?\nA. \u6709\u670d\u7528\u5b89\u7720\u85e5\u7269\u7684\u500b\u6848\u9700\u8981\u6ce8\u610f\u5176\u99d5\u99db\u6c7d\u6a5f\u8eca\u7684\u5b89\u5168\u6027\nB. Zolpidem\u4ee3\u8b1d\u901f\u7387\u7684\u5feb\u6162\u6709\u6027\u5225\u5dee\u7570\nC. \u7f8e\u570b\u98df\u54c1\u85e5\u7269\u7ba1\u7406\u5c40(FDA)\u5efa\u8b70\u5973\u6027\u7684Zolpidem\u8d77\u59cb\u7528\u91cf\u8981\u6bd4\u4e00\u822c\u7537\u6027\u5c11\u4e00\u534a\nD. \u500b\u6848\u5c0d\u65bc\u99d5\u99db\u529f\u80fd\u969c\u7919\u6709\u53ef\u9760\u7684\u81ea\u89ba(self-perception)\nE. \u7761\u7720\u4e0d\u8db3\u6216\u662f\u4f75\u7528\u9152\u7cbe\u6216\u5176\u4ed6\u5177\u6709\u93ae\u5b9a\u526f\u4f5c\u7528\u7684\u85e5\u7269\u540c\u6a23\u4e5f\u6703\u5f71\u97ff\u99d5\u99db\u5b89\u5168\n": "(D)", "107-7.\n\u4e0b\u5217\u54ea\u4e09\u7a2e\u6297\u6182\u9b31\u85e5\u7269\uff0c\u5728\u8fd1\u671f\u7684\u5927\u898f\u6a21 meta-analysis \u4e2d\uff0c\u5448\u73fe\u51fa\u76f8\u4f3c\u7a0b\u5ea6\u7684\u7642\u6548(efficacy)\uff1f (1). venlafaxine (2). fluvoxamine (3). trazodone (4). sertraline (5). fluoxetine\nA. (1)+(3)+(5)\nB. (2)+(4)+(5)\nC. (2)+(3)+(5)\nD. (1)+(2)+(3)\nE. (3)+(4)+(5)\n": "(C)", "108-1.\n\u95dc\u65bc\u89aa\u5bc6\u95dc\u4fc2\u66b4\u529b(intimate partner violence)\u8207\u81e8\u5e8a\u91ab\u5b78\u7684\u95dc\u806f\u6027\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u66b4\u9732\u65bc\u89aa\u5bc6\u95dc\u4fc2\u66b4\u529b\uff0c\u6703\u589e\u52a0\u7f79\u60a3\u6c23\u5598\u3001\u4e2d\u98a8\u6216\u5fc3\u8840\u7ba1\u75be\u75c5\u7684\u98a8\u96aa\nB. \u500b\u6848\u6709\u7d93\u5e38\u6027\u7684\u982d\u9838\u984f\u9762\u7684\u9aa8\u6298\u6216\u6495\u88c2\u50b7\uff0c\u4e5f\u9700\u8981\u8003\u616e\u89aa\u5bc6\u95dc\u4fc2\u66b4\u529b\u7684\u53ef\u80fd\u6027\nC. \u89aa\u5bc6\u95dc\u4fc2\u66b4\u529b\u4e5f\u53ef\u4ee5\u900f\u904e\u9650\u5236\u53d7\u5bb3\u4f34\u4fb6\u7684\u6c42\u91ab\u884c\u70ba\u4f86\u5448\u73fe\uff0c\u5c0e\u81f4\u53d7\u5bb3\u4f34\u4fb6\u91ab\u7642\u914d\u5408\u5ea6(medical adherence)\u4e0d\u4f73\nD. \u5354\u52a9\u60a3\u8005\u63ed\u9732\u89aa\u5bc6\u95dc\u4fc2\u66b4\u529b\u7d93\u9a57\uff0c\u4e0d\u9700\u8981\u5728\u96b1\u5bc6\u5b89\u5168\u7684\u60c5\u5883\u4e0b\u8a62\u554f\uff0c\u800c\u4e14\u9996\u6b21\u898b\u9762\u5c31\u53ef\u4ee5\u554f\u5f97\u51fa\u4f86\nE. \u719f\u6089\u4e26\u63d0\u4f9b\u8f49\u4ecb\u8cc7\u6e90\uff0c\u5982113\u5c08\u7dda\u6216\u5404\u7e23\u5e02\u5bb6\u5ead\u66b4\u529b\u8207\u6027\u4fb5\u5bb3\u9632\u6cbb\u4e2d\u5fc3\u806f\u7d61\u65b9\u5f0f\uff0c\u6709\u52a9\u65bc\u9632\u7bc4\u89aa\u5bc6\u95dc\u4fc2\u66b4\u529b\n": "(D)", "108-2.\n\u95dc\u65bc\u91cd\u5ea6\u6182\u9b31\u75c7(major depression)\u7684\u75c5\u56e0\u5b78\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u96d9\u80de\u80ce\u7814\u7a76\u5448\u73fe\u4e2d\u7b49\u7a0b\u5ea6\u7684\u907a\u50b3\u7387 (moderate heritability)\nB. \u6d77\u99ac\u8ff4\u9ad4\u7a4d(hippocampal volume)\u6e1b\u5c11\u662f\u5728\u5927\u8166\u7d50\u69cb\u4e0a\u4e00\u81f4\u7684\u767c\u73fe\nC. \u5728\u529f\u80fd\u6027\u8166\u9020\u5f71\u7814\u7a76\u5e38\u767c\u73fe\u674f\u4ec1\u6838(amygdala)\u6d3b\u6027\u589e\u52a0\nD. \u8fd1\u5e74\u5168\u57fa\u56e0\u7d44\u95dc\u806f\u6027\u5206\u6790(GWAS)\u5df2\u7d93\u627e\u5230\u5927\u91cf\u53ef\u91cd\u8907\u9a57\u8b49\u7684\u81f4\u75c5\u57fa\u56e0\u4f4d\u9ede\nE. \u8fd1\u5e74\u7814\u7a76\u767c\u73fe\u767c\u708e\u53cd\u61c9\u4e5f\u8207\u91cd\u5ea6\u6182\u9b31\u75c7\u75c5\u56e0\u76f8\u95dc\n": "(D)", "108-3.\n\u95dc\u65bc\u6182\u9b31\u75c7\u7684\u5fc3\u7406\u6cbb\u7642\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u5728\u6182\u9b31\u75c7\u7684\u5fc3\u7406\u6cbb\u7642\u4e2d\uff0c\u8a8d\u77e5\u884c\u70ba\u6cbb\u7642(CBT)\u4ee5\u53ca\u4eba\u969b\u95dc\u4fc2\u6cbb\u7642(IPT)\u662f\u5169\u7a2e\u5e38\u898b\u7684\u6cbb\u7642\u6a21\u5f0f\nB. \u5c0d\u65bc\u75c5\u60c5\u8f03\u56b4\u91cd\u7684\u6182\u9b31\u75c7\u60a3\u8005\uff0c\u75c5\u4eba\u96e3\u4ee5\u6295\u5165(engage)\u5fc3\u7406\u6cbb\u7642\u904e\u7a0b\uff0c\u6545\u50c5\u4f7f\u7528\u5fc3\u7406\u6cbb\u7642\u7684\u7642\u6548\u4e0d\u4f73\nC. \u76ee\u524d\u5b78\u754c\u53ef\u4ee5\u6e05\u695a\u5340\u5206\u4e0d\u540c\u5fc3\u7406\u6cbb\u7642\u6a21\u5f0f\u7642\u6548\u7684\u5dee\u7570\u6240\u5728\nD. \u5c0d\u65bc\u6bd4\u8f03\u8f15\u7684\u6182\u9b31\u75c7\uff0c\u5fc3\u7406\u6cbb\u7642\u8207\u85e5\u7269\u6cbb\u7642\u7684\u6548\u679c\u985e\u4f3c\nE. \u4e0d\u540c\u5fc3\u7406\u6cbb\u7642\u6a21\u5f0f\u5171\u540c\u7684\u7642\u6548\u95dc\u9375\u4e0d\u5916\u4e4e\u8b93\u500b\u6848\u611f\u5230\u6eab\u6696\u3001\u6b63\u5411\u3001\u4ee5\u53ca\u771f\u8aa0\u7684\u7167\u9867\n": "(C)", "108-4.\n\u95dc\u65bc\u6182\u9b31\u75c7\u7684\u751f\u7269\u6027\u6cbb\u7642\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u9078\u64c7\u6027\u8840\u6e05\u7d20\u518d\u5438\u6536\u6291\u5236\u5291(SSRI)\u5e38\u898b\u7684\u526f\u4f5c\u7528\u53ef\u80fd\u5305\u62ec\u6027\u529f\u80fd\u969c\u7919\u3001\u5641\u5fc3\u3001\u982d\u75db\u3001\u9ad4\u91cd\u4e0a\u5347\nB. \u5927\u7d04\u6709\u4e09\u5206\u4e4b\u4e00\u7684\u75c5\u60a3\uff0c\u53ef\u4ee5\u85c9\u7531\u91ab\u5e2b\u8655\u65b9\u7684\u7b2c\u4e00\u7a2e\u6297\u6182\u9b31\u85e5\u7372\u5f97\u75ca\u7652(full remission)\nC. \u66fe\u6709\u570b\u5916\u5927\u578b\u968e\u6bb5\u6027\u85e5\u7269\u8a66\u9a57\u7814\u7a76\u7d50\u679c\u5448\u73fe\uff0c\u5728\u5617\u8a66\u4e86\u56db\u7a2e\u4e0d\u540c\u7684\u6297\u6182\u9b31\u85e5\u7269\u5f8c\uff0c\u7d2f\u7a4d\u8d77\u4f86\u4e5f\u53ea\u6709\u4e8c\u5206\u4e4b\u4e00\u7684\u75c5\u60a3\u7372\u5f97\u75ca\u7652\nD. \u70ba\u4e86\u56e0\u61c9\u55ae\u4e00\u7dda\u6297\u6182\u9b31\u85e5\u7269\u7642\u6548\u4e0d\u5f70\u7684\u554f\u984c\uff0c\u6709\u6642\u5019\u5f97\u5617\u8a66augmentation\uff0c\u4f8b\u5982\u6297\u6182\u9b31\u85e5\u7269\u5408\u4f75lithium\u6216\u662f\u90e8\u5206atypical antipsychotics\nE. \u591a\u91cd\u85e5\u7269\u6cbb\u7642\u53cd\u61c9\u4e0d\u4f73\u6216\u662f\u81ea\u6bba\u98a8\u96aa\u8f03\u9ad8\u7684\u60a3\u8005\uff0c\u53ef\u4ee5\u8003\u616e\u96fb\u6c23\u75d9\u6523\u6cbb\u7642\u6cd5(ECT)\n": "(C)", "108-5.\n\u95dc\u65bc\u5ee3\u7fa9\u7684\u7cbe\u795e\u75c5(psychotic disorders)\u985e\u7fa4\u5404\u7a2e\u75be\u60a3\u7684\u7d42\u751f\u76db\u884c\u7387(lifetime prevalence)\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u601d\u89ba\u5931\u8abf\u75c7(schizophrenia)\uff1a0.30%-0.87%\nB. \u5e36\u6709\u7cbe\u795e\u75c5\u7279\u5fb5\u7684\u96d9\u6975\u60c5\u611f\u75be\u60a3(bipolar disorder with psychotic feature)\uff1a0.12%\nC. \u5e36\u6709\u7cbe\u795e\u75c5\u7279\u5fb5\u7684\u91cd\u5ea6\u6182\u9b31\u75c7(major depressive disorder with psychotic feature):\uff1a0.33%\nD. \u5984\u60f3\u75c7(delusional disorder)\uff1a0.18%\nE. \u7522\u5f8c\u7cbe\u795e\u75c5(postpartum psychosis)\uff1a7%\n": "(E)", "108-6.\n\u95dc\u65bc\u601d\u89ba\u5931\u8abf\u75c7(schizophrenia)\u7684\u5fc3\u7406\u6cbb\u7642\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u76ee\u524d\u5b78\u754c\u652f\u6301\u55ae\u7d14\u4ee5\u5fc3\u7406\u6cbb\u7642\u65b9\u5f0f\u6cbb\u7642\u601d\u89ba\u5931\u8abf\u75c7\nB. \u8a8d\u77e5\u884c\u70ba\u6cbb\u7642(CBT)\u88ab\u8b49\u5be6\u53ef\u4ee5\u6e1b\u8f15\u60a3\u8005\u4f86\u81ea\u5e7b\u807d\u6216\u5984\u60f3\u7684\u75db\u82e6\nC. \u5bb6\u65cf\u7cbe\u795e\u885b\u6559(family psychoeducation)\u6709\u52a9\u65bc\u5bb6\u65cf\u6210\u54e1\u652f\u6301\u75c5\u60a3\u8d70\u5411\u91cd\u5efa\u4e4b\u8def\nD. \u793e\u4ea4\u6280\u5de7\u8a13\u7df4(social skill training)\u9069\u5408\u75c7\u72c0\u56b4\u91cd\u7684\u6025\u6027\u671f\u75c5\u60a3\nE. \u91dd\u5c0d\u6703\u5f15\u767c\u7cbe\u795e\u75c5\u75c7\u72c0\u7684\u523a\u6fc0\uff0c\u65bd\u4ee5\u56b4\u8b39\u7684\u884c\u70ba\u66b4\u9732\u6cbb\u7642(behavioral exposure)\uff0c\u6709\u52a9\u65bc\u5efa\u7acb\u73fe\u5be6\u8003\u9a57\u611f(reality testing)\n": "(A)", "108-7.\n\u4e0b\u5217\u54ea\u5e7e\u500b\u85e5\u7269\u6709\u7372\u5f97\u7f8e\u570bFDA\u6cbb\u7642\u9152\u7cbe\u4f7f\u7528\u75be\u60a3(alcohol use disorder)\u7684\u8a31\u53ef\u8b49\uff1f(1)Vareniciline (2)Naltrexone (3)Disulfiram (4)Baclofen (5)Acamprosate\nA. (1)+(2)+(3)\nB. (1)+(3)+(5)\nC. (2)+(3)+(4)\nD. (2)+(3)+(5)\nE. (3)+(4)+(5)\n": "(D)", "109-187.\u95dc\u65bc\u9152\u7cbe\u4f7f\u7528\u75be\u60a3(alcohol use disorder, AUD)\u7684\u6cbb\u7642\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f    \nA.\u76ee\u524d\u5be6\u8b49\u6709\u6548\u7684\u793e\u6703\u5fc3\u7406\u6cbb\u7642 (psychosocial treatment )\uff0c\u5305\u62ec\u77ed\u671f\u8aee\u5546 (brief counseling )\u3001\u5f37\u5316\u52d5\u6a5f\n\u6cbb\u7642(motivational enhancement therapy )\u3001\u4ee5\u53ca\u884c\u70ba\u7d04\u5b9a (behavioral contract )\u7b49\nB.\u7f8e\u570bFDA\u6216\u6b50\u6d32EMA\u6838\u51c6\u7684AUD\u6cbb\u7642\u85e5\u7269\uff0c\u5305\u62ecNaltrexone\u808c\u8089\u6ce8\u5c04\nC.Disulfiram\u9069\u7528\u65bc\u4ecd\u6301\u7e8c\u5927\u91cf\u98f2\u9152\u7684\u500b\u6848\nD.Topiramate\u6709\u6548\u6212\u9152\u7684\u6a5f\u8f49\uff0c\u8207GluK1\u7684\u57fa\u56e0\u591a\u578b\u6027\u76f8\u95dc\nE.\u6b62\u5410\u5291Ondansetron\u5c0d\u65bc\u65e9\u767c\u578b\u9152\u7cbe\u4f7f\u7528\u75be\u60a3(early-onset AUD)\u5177\u6709\u6cbb\u7642\u6f5b\u529b\n": "[C]", "109-188.\u95dc\u65bcCOVID-19\u5927\u6d41\u884c\u75ab\u60c5\u7684\u5fc3\u7406\u885d\u64ca\u8207\u9632\u6cbb\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f    \nA.\u5373\u4f7f\u75ab\u60c5\u904e\u53bb\uff0c\u5fc3\u7406\u885d\u64ca\u53ef\u80fd\u6301\u7e8c\nB.\u8fc5\u901f\u6709\u6548\u7684\u6e9d\u901a (effective and rapid communication )\u4ee5\u53ca\u76e1\u53ef\u80fd\u63d0\u4f9b\u5145\u8db3\u7684\u8cc7\u8a0a\u662f\u964d\u4f4e\u5fc3\u7406\u885d\u64ca\u7684\u91cd\n\u8981\u5143\u7d20\nC.\u81ea\u9858\u6027\u6aa2\u75ab(voluntary quarantine)\u7684\u500b\u6848\u60c5\u7dd2\u75db\u82e6\u8f03\u5c11\nD.\u516c\u5171\u885b\u751f\u5b98\u54e1\u4e0d\u61c9\u8a72\u5f37\u8abf\u81ea\u6211\u9694\u96e2(self-isolating)\u6240\u5c55\u73fe\u7684\u5229\u4ed6(altruism)\u7cbe\u795e\nE.\u91ab\u7642\u6a5f\u69cb\u9700\u8981\u7279\u5225\u95dc\u6ce8\u91ab\u8b77\u4eba\u54e1\u7684\u5fc3\u7406\u5065\u5eb7\u9700\u6c42\n": "[D]", "109-189.\u95dc\u65bc\u53ad\u98df\u75c7(anorexia nervosa)\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u975e\uff1f    \nA.\u81e8\u5e8a\u8868\u73fe\u70ba\u6975\u5ea6\u5730\u5bb3\u6015\u9ad4\u91cd\u589e\u52a0\uff0c\u81ea\u6211\u9650\u5236\u71b1\u91cf\u651d\u53d6\uff0c\u5c0e\u81f4\u71df\u990a\u4e0d\u826f\nB.\u7cbe\u795e\u4f5c\u7528\u85e5\u7269(psychotropic medications)\u5c0d\u65bc\u5e6b\u52a9\u53ad\u98df\u75c7\u500b\u6848\u589e\u52a0\u9ad4\u91cd\u8207\u964d\u4f4e\u6182\u9b31\u60c5\u7dd2\u6709\u660e\u986f\u7642\u6548\nC.\u61c9\u63d0\u4f9b\u5fc3\u7406\u6cbb\u7642\u4ecb\u5165 (psychotherapeutic approach )\u4ee5\u53ca\u91dd\u5c0d\u5b69\u7ae5\u6216\u9752\u5c11\u5e74\u75c5\u60a3\u7684\u5bb6\u65cf\u6cbb\n\u7642(family-based therapy )\nD.\u56b4\u91cd\u812b\u6c34\uff0c\u96fb\u89e3\u8cea\u4e0d\u5e73\u8861\uff0c\u5fc3\u5f8b\u904e\u6162\uff0c\u81ea\u6bba\u98a8\u96aa\uff0c\u4ee5\u53caBMI\u5c0f\u65bc15\u7b49\uff0c\u5e38\u5e38\u662f\u75c5\u60a3\u9700\u8981\u4f4f\u9662\u7684\u539f\u56e0\nE.\u53ad\u98df\u75c7\u6709\u5169\u500b\u4e9e\u578b \uff0c\u9650\u5236\u98f2\u98df\u578b (restricting type )\u4ee5\u53ca\u66b4\u98df\u50ac\u5410\u578b (binge-eating and purging type )\uff0c\u500b\n\u6848\u8f03\u5e38\u662f\u7531\u9650\u5236\u578b\u8f49\u70ba\u66b4\u98df\u50ac\u5410\u578b\n": "[B]", "109-190.\u95dc\u65bc\u601d\u89ba\u5931\u8abf\u75c7(schizophrenia)\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f    \nA.\u5927\u7d04\u67091%\u4eba\u53e3\u7b26\u5408\u9019\u500b\u8a3a\u65b7\nB.\u5984\u60f3(delusion)\u3001\u5e7b\u89ba(hallucination)\u3001\u4ee5\u53ca\u7f3a\u4e4f\u7d44\u7e54\u7684\u8a00\u8a9e(disorganized speech)\u662f\u4e3b\u8981\u75c7\u72c0\nC.\u7814\u7a76\u767c\u73fe\u75c5\u60a3\u53ef\u80fd\u6709\u5927\u8166\u524d\u984d\u8449(prefrontal)\u7070\u8cea\u6e1b\u5c11\u73fe\u8c61   \nD.\u6295\u4e88\u6297\u7cbe\u795e\u75c5\u85e5\u7269(antipsychotic medications)\u5f8c\uff0c\u5e7b\u807d\u5984\u60f3\u5e38\u57282\u5929\u81f34\u5929\u5167\u53ef\u7372\u660e\u986f\u7de9\u89e3\nE.\u5927\u7d04\u670910%\u523030%\u7684\u75c5\u60a3\u5c0d\u65bc\u6297\u7cbe\u795e\u75c5\u85e5\u7269\u6cbb\u7642\u53cd\u61c9\u6709\u9650\n": "[D]", "109-191.\u5728\u9580\u8a3a\u7be9\u6aa2\u500b\u6848\u662f\u5426\u6709\u6182\u9b31\u75c7 \uff0c\u5b78\u8005\u5e38\u7528PHQ -2\u554f\u5377\uff0c\u7be9\u6aa2\u984c\u76ee \u300c\u4e0d\u5305\u62ec\u300d\u4e0b\u5217\u54ea\u4e09\u53e5\uff1f\u300c\u5728\u904e\u53bb\u5169\u5468\u7576\n\u4e2d\uff0c\u60a8\u6709\u591a\u5e38\u88ab\u4e0b\u5217\u7684\u554f\u984c\u56f0\u64fe... \u300d\n(1) \u7121\u6cd5\u96c6\u4e2d\u6ce8\u610f\u529b\n(2) \u96e3\u4ee5\u5165\u7761\u6216\u7761\u5f97\u592a\u591a\n(3) \u505a\u4e8b\u5f88\u5c11\u6709\u52d5\u6a5f\u6216\u6a02\u8da3\n(4) \u98df\u617e\u4e0d\u4f73\u4e0d\u60f3\u5403\u98ef\n(5) \u89ba\u5f97\u60c5\u7dd2\u4f4e\u843d\u6182\u9b31\u6216\u6c92\u6709\u5e0c\u671b   \nA.(1)+(2)+(3)\nB.(2)+(3)+(4)\nC.(1)+(2)+(4)\nD.(3)+(4)+(5)\nE.(1)+(3)+(5)\n": "[C]", "109-192.\u95dc\u65bc\u81ea\u6bba\u9632\u6cbb\u4e0b\u5217\u4f55\u8005\u70ba\u5c0d \uff1f(1) \u5728\u525b\u88ab\u8a3a\u65b7\u7f79\u60a3\u764c\u75c7\u5f8c\u4e00\u5468\u5167\u53ef\u80fd\u6709\u7279\u5225\u9ad8\u7684\u81ea\u6bba\u98a8\u96aa \uff1b(2) \u5efa\u7acb\u4e26\u7dad\u6301\n\u6cbb\u7642\u95dc\u4fc2\u662f\u81ea\u6bba\u9632\u6cbb\u91cd\u8981\u56e0\u7d20\u4e4b\u4e00 \uff1b(3) \u9650\u5236\u81f4\u547d\u5de5\u5177\u53ef\u5f97\u6027 \uff0c\u4f8b\u5982\u7ba1\u5236\u69cd\u679d\u6216\u505c\u6b62\u8ca9\u552e\u5287\u6bd2\u8fb2\u85e5 \uff0c\u5c0d\u9632\n\u6cbb\u81ea\u6bba\u6c92\u6709\u5e6b\u52a9 \uff1b(4) \u76ee\u524d\u6709\u5f88\u5f37\u7684\u8b49\u64da\u652f\u6301\u5728\u4e00\u822c\u91ab\u5b78\u60c5\u5883 (primary care )\u548c\u6025\u8a3a\u5ba4 \uff0c\u4f7f\u7528\u91cf\u8868\u5e38\u898f\u7be9\u6aa2\n\u81ea\u6bba\u98a8\u96aa\u53ef\u4ee5\u6709\u6548\u9632\u6cbb\u81ea\u6bba \uff1b(5) \u92f0\u9e7d(Lithium)\u66fe\u7d93\u88ab\u8b49\u660e\u53ef\u4ee5\u964d\u4f4e\u96d9\u6975\u75c7 (bipolar disorder )\u75c5\u60a3\u7684\u81ea\u6bba\u98a8\n\u96aa\u3002   \nA.(1)+(2)+(3)\nB.(2)+(3)+(4)\nC.(1)+(4)+(5)\nD.(3)+(4)+(5)\nE.(1)+(2)+(5)\n": "[E]", "109-193.\u4e0b\u5217\u6297\u6182\u9b31\u85e5\u7269\u8207\u526f\u4f5c\u7528\u7684\u914d\u5c0d\uff0c\u54ea \u3127\u7d44\u662f\u4e0d\u5e38\u898b\u7684\uff1f    \nA.\u9078\u64c7\u6027\u8840\u6e05\u7d20\u6291\u5236\u5291 (Selective Serotonin Reuptake Inhbitor: SSRI )\uff1a\u8178\u80c3\u4e0d\u9069 (nausea and other GI \neffects )\nB.\u4e09\u74b0\u6297\u6182\u9b31\u85e5(Tricyclic antidepressants: TCA):\uff1a\u53e3\u4e7e\u4fbf\u79d8(dry mouth and constipation)\nC.\u9078\u64c7\u6027\u8840\u6e05\u7d20\u6291\u5236\u5291(Selective Serotonin Reuptake Inhibitor: SSRI)\uff1a\u982d\u75db(headache)\nD.\u9078\u64c7\u6027\u65b0\u814e\u4e0a\u817a\u7d20\u8207\u8840\u6e05\u7d20\u518d\u5438\u6536\u6291\u5236\u5291 (Selective Norepinephrine /Serotonin Reuptake Inhibitors: \nSNRI): \u9670\u8396\u7570\u5e38\u52c3\u8d77 (priapism)\nE.\u4e09\u74b0\u6297\u6182\u9b31\u85e5(Tricyclic antidepressants: TCA)\uff1a\u9ad4\u91cd\u4e0a\u5347(weight gain)\n": "[D]", "110-151.\u95dc\u65bc\u91ab\u7642\u4eba\u54e1\u9762\u5c0d\u56b4\u91cd\u7279\u6b8a\u50b3\u67d3\u6027\u80ba\u708e\u6aa2\u75ab\u9694\u96e2\u7684\u5fc3\u7406\u58d3\u529b\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f    \nA.\u9694\u96e2\u6aa2\u75ab\u6642\u9593 (duration of quarantine )\u8d8a\u9577\uff0c\u53ef\u80fd\u589e\u52a0\u5275\u50b7\u5f8c\u58d3\u529b\u75c7\u72c0 (post-traumatic stress \nsymptoms )\u98a8\u96aa\u3002\nB.\u8271\u9245\u5de5\u4f5c\u74b0\u5883\u53ca\u5167\u5728\u50f9\u503c\u885d\u7a81\u662f\u5fc3\u7406\u5c64\u9762\u885d\u64ca\u4f86\u6e90\u4e4b\u4e00\u3002\nC.\u88ab\u6aa2\u75ab\u9694\u96e2\u7684\u91ab\u7642\u4eba\u54e1 \uff0c\u6240\u53d7\u5230\u6a19\u7c64\u5316 (stigmatization )\u8ca0\u9762\u5f71\u97ff\u7a0b\u5ea6 \uff0c\u660e\u986f\u4f4e\u65bc\u88ab\u6aa2\u75ab\u9694\u96e2\u7684\u4e00\u822c\u5927\n\u773e\u3002\nD.\u91ab\u7642\u4eba\u54e1\u82e5\u66fe\u7d93\u6b77\u904e\u6aa2\u75ab\u9694\u96e2\uff0c\u7121\u8ad6\u662f\u5426\u88ab\u78ba\u8a3a\uff0c\u5fc3\u7406\u5c64\u9762\u885d\u64ca\u98a8\u96aa\u53ef\u80fd\u8f03\u4e00\u822c\u65cf\u7fa4\u70ba\u9ad8\u3002\nE.\u5c0d\u65bc\u75ab\u60c5\u671f\u9593\u9577\u671f\u65bc\u7b2c\u4e00\u7dda\u5de5\u4f5c\u4e4b\u91ab\u7642\u4eba\u54e1\uff0c\u5fc3\u7406\u5065\u5eb7\u95dc\u61f7\u9700\u8981\u7279\u5225\u88ab\u91cd\u8996\u3002\n": "[C]", "110-152.\u95dc\u65bc\u7126\u616e\u75be\u60a3(anxiety disorders)\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f    \nA.\u9078\u64c7\u6027\u5931\u8a9e\u75c7(selective mutism)\u4e5f\u662f\u4e00\u7a2e\u7126\u616e\u75be\u60a3\u3002\nB.\u793e\u4ea4\u7126\u616e\u75c7(social anxiety disorder)\u7684\u767c\u75c5\u5e74\u9f61\u591a\u5728\u9752\u6625\u671f\u65e9\u671f(early adolescence)\u3002\nC.Selective serotonin reuptake inhibitors (SSRIs) \u4ee5\u53ca Serotonin \u2013noradrenaline reuptake inhibitors \n(SNRIs)\u662f\u5305\u62ec\u793e\u4ea4\u7126\u616e\u75c7\u4ee5\u53ca\u6050\u614c\u75c7\u7b49\u7126\u616e\u75be\u60a3\u7684\u6cbb\u7642\u9078\u9805 \u3002\nD.\u7126\u616e\u75be\u60a3\u7684\u6cbb\u7642\u6548\u679c\uff0c\u76ee\u524d\u8b49\u64da\u50be\u5411\u65bc\u85e5\u7269\u6cbb\u7642\u986f\u8457\u512a\u65bc\u5fc3\u7406\u6cbb\u7642\u3002\nE.\u7672\u7647(epilepsy)\u7684\u524d\u5146(aura)\u6216\u662f\u8d77\u59cb\u75c7\u72c0\uff0c\u4e5f\u6709\u53ef\u80fd\u4ee5\u7126\u616e\u75c7\u72c0\u4f86\u5448\u73fe\u3002\n": "[D]", "110-153.\u95dc\u65bc\u5404\u7a2e\u98f2\u98df\u75be\u60a3(eating disorders)\u7684\u63cf\u8ff0\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f    \nA.\u98f2\u98df\u75be\u60a3\u500b\u6848\u5e38\u5171\u75c5\u7126\u616e\u4ee5\u53ca\u6182\u9b31\u75be\u60a3\u3002   \nB.\u53cd\u82bb\u969c\u7919 (rumination disorder) \u662f\u56e0\u70ba\u5641\u5fc3 (nausea)\uff0c\u4e0d\u81ea\u4e3b\u4e7e\u5614 (involuntary retching )\uff0c\u6216\u662f\u53cd\u80c3\u4f5c\n\u5614(disgust)\uff0c\u800c\u5c07\u5403\u9032\u53bb\u7684\u98df\u7269\u53cd\u6d41\u51fa\u4f86 (regurgitation )\u3002\nC.\u53ad\u98df\u75c7(anorexia nervosa )\u60a3\u8005\u65bc\u6d88\u5316\u9053\u7684\u75c7\u72c0\u5305\u62ec\u5ef6\u9072\u6027\u80c3\u6392\u7a7a (delayed gastric emptying )\u4ee5\u53ca\u80c3\u524d\n\u5ead\u8815\u52d5\u7570\u5e38 (altered antral motility )\u3002\nD.\u66b4\u98df\u75c7(bulimia nervosa )\u60a3\u8005\u65bc\u4ee3\u8b1d\u751f\u5316\u6aa2\u9a57\u7684\u7279\u5fb5\u53ef\u80fd\u5305\u62ec\u56e0\u70ba\u7009\u5291\u6feb\u7528\u5f15\u767c\u4e4b\u4ee3\u8b1d\u6027\u9178\u4e2d\n\u6bd2(metabolic acidosis )\u4ee5\u53ca\u904e\u5ea6\u5614\u5410\u9020\u6210\u7684\u4ee3\u8b1d\u6027\u9e7c\u4e2d\u6bd2 (metabolic alkalosis )\u3002\nE.\u8a8d\u77e5\u884c\u70ba\u6cbb\u7642(cognitive behavioural therapy, CBT)\u662f\u98f2\u98df\u75be\u60a3\u6cbb\u7642\u7684\u9996\u9078\u65b9\u5f0f\u4e4b\u4e00\u3002\n": "[B]", "110-154.\u95dc\u65bc\u7cbe\u795e\u79d1\u8a3a\u65b7\u7cfb\u7d71DSM -5\u5b9a\u7fa9\u7684\u8eab\u9ad4\u75c7\u72c0\u75be\u60a3 (somatic symptom disorders )\uff0c\u4e5f\u5c31\u662f\u904e\u53bb\u4fd7\u7a31\u591a\u91cd\u8eab\u9ad4\n\u62b1\u6028(multiple somatic compliants )\uff0c\u6b47\u65af\u5e95\u91cc\u75c7 (hysteria)\uff0c\u6216\u662f\u8eab\u9ad4\u5316\u75c7 (somoatoform disorder )\u500b\n\u6848\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u6b63\u78ba \uff1a(1)\u5373\u4f7f\u75c5\u60a3\u8eab\u9ad4\u62b1\u6028\u67e5\u6709\u5be6\u64da \uff0c\u4f46\u500b\u6848\u5c0d\u5065\u5eb7\u6216\u75c7\u72c0\u6709\u6301\u7e8c\u6027\u9ad8\u5ea6\u7126\u616e \uff0c\u6295\u6ce8\u4e86\n\u904e\u591a\u7684\u6642\u9593\u548c\u7cbe\u529b \uff0c\u4e5f\u53ef\u4ee5\u7b26\u5408\u9019\u500b\u8a3a\u65b7 (2)\u5927\u91cf\u63a2\u7d22\u6027\u6aa2\u67e5\u6709\u52a9\u5b89\u64ab\u75c5\u60a3 (3)\u8207\u75c5\u60a3\u5c0d\u8cea (confront)\u8eab\u9ad4\n\u4e0d\u9069\u7684\u771f\u5be6\u6027 \uff0c\u6709\u52a9\u65bc\u6e1b\u7de9\u500b\u6848\u7126\u616e (4)\u90e8\u4efd\u75c5\u60a3\u53ef\u80fd\u5c0d\u65bc\u6297\u6182\u9b31\u85e5\u7269\u6709\u6cbb\u7642\u53cd\u61c9 \uff0c\u4f46\u5be6\u8b49\u6587\u737b\u4ecd\u4e0d\u8db3 \n(5)\u6301\u7e8c\u898f\u5f8b\u7684\u60c5\u7dd2\u652f\u6301 \uff0c\u4e26\u9010\u6f38\u767c\u5c55\u4e0d\u5b8c\u5168\u4ee5\u5c0b\u6c42\u8a3a\u65b7\u4ecb\u5165\u70ba\u76ee\u7684\u4e4b\u898f\u5247\u56de\u8a3a \uff0c\u6709\u52a9\u65bc\u500b\u6848\u8abf\u6574\u884c\u70ba \u3002   \nA.(1)+(2)+(3)\u3002\nB.(2)+(3)+(5)\u3002\nC.(3)+(4)+(5)\u3002\nD.(1)+(3)+(4)\u3002\nE.(1)+(4)+(5)\u3002\n": "[E]", "110-155.\u95dc\u65bc\u6297\u6182\u9b31\u85e5\u7269\u7684\u5e38\u898b\u526f\u4f5c\u7528 \uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u771f \uff1f(1)Fluoxetine (Prozac)\uff1a\u5641\u5fc3 (2)Doxepin \n(Sinequan )\uff1a\u8179\u7009 (3)Mirtazapine (Remeron )\uff1a\u9ad4\u91cd\u4e0a\u5347 (4)Duloxetine (Cymbalta )\uff1a\u982d\u75db (5)Bupropion \n(Wellbutrin )\uff1a\u6027\u529f\u80fd\u969c\u7919 \u3002   \nA.(1)+(2)+(3)\u3002\nB.(1)+(3)+(5)\u3002\nC.(2)+(3)+(4)\u3002\nD.(1)+(3)+(4)\u3002\nE.(3)+(4)+(5)\u3002\n": "[D]", "111-151.\u95dc\u65bc\u81ea\u6bba\u9632\u6cbb\u5de5\u4f5c\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f    \nA.\u5f71\u8996\u540d\u4eba\u81ea\u6bba\u7684\u65b0\u805e\u5831\u5c0e\u8207\u81ea\u6bba\u7387\u589e\u52a0\u6709\u95dc\u3002\nB.\u9810\u9632\u81ea\u6bba\u5fc5\u9808\u5305\u62ec\u81e8\u5e8a\u8207\u793e\u6703\u652f\u6301\u7b49\u591a\u9762\u5411\u6295\u5165\u3002\nC.\u6c23\u5019\u8b8a\u9077(climate change)\u5c0e\u81f4\u4e4b\u81ea\u6bba\u548c\u81ea\u6b98\uff0c\u662f\u4e00\u500b\u9010\u6f38\u88ab\u91cd\u8996\u7684\u5168\u7403\u95dc\u9375\u98a8\u96aa\u56e0\u7d20\u3002\nD.\u4f7f\u7528\u85e5\u7269\u4f86\u59a5\u5584\u6cbb\u7642\u6f5b\u5728\u7684\u7cbe\u795e\u75be\u60a3\uff0c\u7121\u52a9\u65bc\u9810\u9632\u81ea\u6bba\u3002\nE.\u5c0d\u91ab\u7642\u4fdd\u5065\u5c08\u696d\u4eba\u54e1\u800c\u8a00 \uff0c\u7576\u6709\u60a3\u8005\u4e0d\u5e78\u81ea\u6bba\u8eab\u4ea1 \uff0c\u53ef\u80fd\u6703\u5728\u60c5\u7dd2\u8207\u5c08\u696d\u5de5\u4f5c\u4e0a\u9020\u6210\u885d\u64ca \uff0c\u70ba\u91ab\u7642\u4fdd\n\u5065\u5c08\u696d\u4eba\u54e1\u63d0\u4f9b\u652f\u6301\u4ee5\u53ca\u8eab\u5fc3\u7167\u9867\u662f\u91cd\u8981\u7684 \u3002   \n": "[D]", "111-152.\u95dc\u65bc\u6cbb\u7642 \u300c\u8ec0\u9ad4\u75c7\u72c0\u75be\u60a3 \u300d(somatic symptom disorder )\uff0c\u4e5f\u5c31\u662f\u904e\u53bb\u7a31\u4e4b\u70ba \u300c\u8eab\u9ad4\u5316\u75c7 \u300d(somatoform \ndisorder)\u9019\u985e\u5177\u6709 \u300c\u67e5\u7121\u5be6\u64da \u300d\u6216\u300c\u8a00\u904e\u5176\u5be6 \u300d\u8eab\u9ad4\u62b1\u6028\u7684\u60a3\u8005 \uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e \uff1f   \nA.\u8ec0\u9ad4\u75c7\u72c0\u75be\u60a3\u500b\u6848\uff0c\u7d93\u5e38\u63a5\u53d7\u8a31\u591a\u8a3a\u65b7\u6aa2\u67e5\u548c\u63a2\u7d22\u6027\u624b\u8853\uff0c\u8a66\u5716\u627e\u5230\u4ed6\u5011\u300c\u771f\u6b63\u300d\u7684\u75be\u75c5\u3002\nB.\u6297\u6182\u9b31\u85e5\u7269\u5c0d\u65bc\u8ec0\u9ad4\u75c7\u72c0\u75be\u60a3\u500b\u6848\u7684\u75c7\u72c0\u7de9\u89e3\u5b8c\u5168\u7121\u6548\u3002\nC.\u4efb\u4f55\u8207\u60a3\u8005\u5c0d\u8cea (confrontation )\u5176\u5fc3\u7406\u6b78\u56e0\u7684\u5617\u8a66 \uff0c\u901a\u5e38\u90fd\u6703\u7522\u751f\u7f9e\u8fb1\u611f \uff0c\u5c0e\u81f4\u60a3\u8005\u653e\u68c4\u8a72\u91ab\u7642\u4eba\u54e1\n\u7684\u6cbb\u7642\uff0c\u6301\u7e8c\u904a\u8d70\u5c31\u91ab \u3002\nD.\u6bd4\u8f03\u6709\u5e6b\u52a9\u7684\u7b56\u7565\u662f\u5f15\u5165\u5fc3\u7406\u56e0\u679c\u95dc\u4fc2\u4f5c\u70ba\u8a0e\u8ad6\u9451\u5225\u8a3a\u65b7\u4e2d\u7684\u8a31\u591a\u53ef\u80fd\u89e3\u91cb\u4e4b\u4e00\u3002\nE.\u5728\u907f\u514d\u5c07\u5fc3\u7406\u56e0\u7d20\u4f5c\u70ba\u60a3\u8005\u8eab\u9ad4\u62b1\u6028\u75c5\u56e0\u552f\u4e00\u89e3\u91cb\u7684\u6c1b\u570d\u4e0b \uff0c\u53ef\u4ee5\u70ba\u60a3\u8005\u4fdd\u7559\u9762\u5b50 \uff0c\u901a\u904e\u9019\u7a2e\u9593\u63a5\u7a00\n\u91cb\u5fc3\u7406\u6b78\u56e0\u7684\u65b9\u5f0f \uff0c\u53cd\u800c\u6709\u6a5f\u6703\u767c\u5c55\u51fa\u8abf\u6574\u60a3\u8005\u751f\u6d3b\u58d3\u529b\u6e90\u7684\u65b9\u6cd5 \u3002\n": "[B]", "111-153.\u95dc\u65bc\u6182\u9b31\u75c7\u8207\u8eab\u9ad4\u75be\u75c5\u7684\u95dc\u806f\u6027\uff0c\u9805\u5217\u4f55\u8005\u70ba\u975e\uff1f    \nA.\u5728\u764c\u75c7\u60a3\u8005\u4e2d \uff0c\u6182\u9b31\u75c7\u7684\u5e73\u5747\u7f79\u75c5\u7387\u53ef\u4ee5\u9ad8\u9054 25 %\uff0c\u800c40-50% \u7684\u80f0\u81df\u764c\u6216\u53e3\u54bd\u764c\u60a3\u8005\u6703\u51fa\u73fe\u6182\u9b31\n\u75c7\u3002\nB.\u80f0\u81df\u764c\u8207\u6182\u9b31\u75c7\u7684\u95dc\u806f\u4e0d\u50c5\u50c5\u7531\u65bc\u60e1\u75c5\u8cea (cachexia )\u5f71\u97ff\uff0c\u8207\u665a\u671f\u80c3\u764c\u60a3\u8005\u76f8\u6bd4 \uff0c\u80f0\u81df\u764c\u60a3\u8005\u7684\u6182\u9b31\n\u75c7\u60a3\u75c5\u7387\u660e\u986f\u8f03\u9ad8 \u3002\nC.\u4e0d\u7a69\u5b9a\u578b\u5fc3\u7d5e\u75db \u3001\u5fc3\u808c\u6897\u585e \u3001\u5fc3\u81df\u7e5e\u9053\u624b\u8853\u6216\u5fc3\u81df\u79fb\u690d\u5f8c\u60a3\u8005 \uff0c\u82e5\u767c\u751f\u6182\u9b31\u75c7\u72c0 \uff0c\u88ab\u8b49\u660e\u6703\u5f71\u97ff\u5eb7\n\u5fa9\uff0c\u4e26\u8207\u65e5\u5f8c\u8f03\u9ad8\u7684\u6b7b\u4ea1\u7387 (mortality )\u548c\u91ab\u7642\u767c\u75c5\u7387 (morbidity )\u76f8\u95dc\u3002\nD.\u7cd6\u5c3f\u75c5\u60a3\u8005\u7684\u6182\u9b31\u75c7\u60a3\u75c5\u7387\u5f9e 8% \u5230 27% \u4e0d\u7b49 \uff0c\u6182\u9b31\u60c5\u7dd2\u7684\u56b4\u91cd\u7a0b\u5ea6 \uff0c\u8207\u9ad8\u8840\u7cd6\u7a0b\u5ea6 (level of \nhyperglycemia )\u548c\u7cd6\u5c3f\u75c5\u4f75\u767c\u75c7\u7684\u98a8\u96aa\u76f8\u95dc \u3002\nE.\u4e09\u74b0\u6297\u6182\u9b31\u85e5(TCA)\u6703\u7522\u751f\u4f4e\u8840\u7cd6\u548c\u5c0d\u78b3\u6c34\u5316\u5408\u7269\u7684\u5acc\u60e1\u3002\n": "[E]", "111-154.\u95dc\u65bc\u96fb\u6c23\u75d9\u6523\u6cbb\u7642\u6cd5 (Electroconvulsive Therapy, ECT )\u7684\u6558\u8ff0\u4e0b\u5217\u4f55\u8005\u70ba\u662f \uff1f\n(1) \u5728\u7279\u5b9a\u65cf\u7fa4\u4e2d \uff0cECT \u53ef\u4ee5\u8fc5\u901f\u6539\u5584\u6182\u9b31 \u3001\u7cbe\u795e\u75c5\u548c\u7dca\u5f35 (catatonia )\u75c7\u72c0\uff0c\u4e26\u53ef\u4ee5\u6e1b\u5c11\u81ea\u6bba\u885d\u52d5\n(2) \u8207 ECT \u76f8\u95dc\u7684\u56b4\u91cd\u4e0d\u826f\u4e8b\u4ef6\u5f88\u7f55\u898b \uff0c\u5305\u62ec\u5fc3\u5f8b\u4e0d\u6574\u8207\u547c\u5438\u7a98\u8feb\u7b49\n(3) \u5728\u4e00\u9805\u6d89\u53ca\u96e3\u6cbb\u578b\u7cbe\u795e\u5206\u88c2\u75c7\u60a3\u8005\u7684\u7814\u7a76\u4e2d \uff0cECT \u6709\u6548\u7387\u5728 80% \u5230 90% \u4e4b\u9593\n(4) ECT \u7684\u4f30\u8a08\u6b7b\u4ea1\u7387\u7d04\u70ba\u6bcf 100 ,000 \u6b21\u6cbb\u7642\u4e2d\u6709 21 \u4eba\u6b7b\u4ea1\n(5) \u73fe\u4ee3\u5316\u7684ECT \u7684\u6cbb\u7642\u6d41\u7a0b\u5305\u62ec\u8a98\u5c0e\u77ed\u66ab\u7684\u5168\u8eab\u9ebb\u9189 \uff08\u901a\u5e38\u6301\u7e8c\u4e0d\u5230 10 \u5206\u9418\uff09\u3001 \u85e5\u7269\u6027\u808c\u8089\u653e\u9b06 \uff0c\u4ee5\n\u53ca\u6301\u7e8c\u76e3\u6e2c\u8840\u6c27\u98fd\u548c\u5ea6 \u3001\u8840\u58d3\u3001\u5fc3\u7387\u548c\u7bc0\u5f8b   \nA.(1)+(2)+(3)\u3002\nB.(1)+(3)+(5)\u3002\nC.(2)+(3)+(4)\u3002\nD.(1)+(2)+(5)\u3002\nE.(3)+(4)+(5)\u3002\n": "[D]", "111-155.\u95dc\u65bc\u8b6b\u5984 (delirium)\u4e0b\u5217\u4f55\u8005\u70ba\u662f \uff1f\n(1) \u4f4f\u9662\u75c5\u60a3\u7684\u8b6b\u5984\u98a8\u96aa\u56e0\u5b50\u5305\u62ec \uff1a\u4f7f\u7528\u8180\u80f1\u5c0e\u7ba1\u63d2\u5165\u8853 \u3001\u8eab\u9ad4\u7d04\u675f \u3001\u7761\u7720\u548c\u611f\u89ba\u525d\u596a \uff0c\u4ee5\u53ca\u6dfb\u52a0\u4e09\u7a2e\u6216\n\u66f4\u591a\u7684\u65b0\u85e5\u7269\n(2) \u8b6b\u5984\u60a3\u8005\u7684\u4f4f\u9662\u6b7b\u4ea1\u7387\u4f30\u8a08\u5728 2% \u5230 4% \u4e4b\u9593\uff0c\u9060\u4f4e\u65bc\u6557\u8840\u75c7\u5f15\u8d77\u7684\u6b7b\u4ea1\u7387\n(3) \u85e5\u7269\u4ecd\u7136\u662f\u8b6b\u5984\u7684\u9810\u9632\u53ca\u4fdd\u8b77\u56e0\u5b50 \uff0c\u5c24\u5176\u662f\u5177\u6709\u6297\u81bd\u9e7c\u6216\u93ae\u975c\u7279\u6027\u7684\u85e5\u7269\n(4) \u76f2\u76ee\u5730\u91dd\u5c0d\u8b6b\u5984\u75c7\u72c0\u9032\u884c\u85e5\u7269\u6cbb\u7642\u53ea\u6703\u5ef6\u9577\u60a3\u8005\u8655\u65bc\u6df7\u4e82\u72c0\u614b\u7684\u6642\u9593 \uff0c\u4e26\u53ef\u80fd\u63a9\u84cb\u91cd\u8981\u7684\u6f5b\u5728\u75c5\u56e0\u8a3a\n\u65b7\u7dda\u7d22\n(5) \u61c9\u907f\u514d\u5316\u5b78\u7d04\u675f (chemical restrain )\uff0c\u5fc5\u8981\u6642\u4f7f\u7528\u6975\u4f4e\u5291\u91cf\u7684\u5178\u578b\u6216\u975e\u5178\u578b\u6297\u7cbe\u795e\u75c5\u85e5\u7269 \uff0c\u4e14\u61c9\u8a72\u7559\u7d66\n\u56b4\u91cd\u8e81\u52d5\u548c\u660e\u986f\u53ef\u80fd\u50b7\u5bb3\u81ea\u5df1\u6216\u5de5\u4f5c\u4eba\u54e1\u7684\u60a3\u8005   \nA.(1)+(2)+(3)\u3002\nB.(1)+(3)+(5)\u3002   \nC.(2)+(3)+(4)\u3002\nD.(3)+(4)+(5)\u3002\nE.(1)+(4)+(5)\u3002\n": "[E]"}